A new way to improve platelet quality

CPT2 upregulators improve platelet quality and longevity by reducing apoptosis and enhancing storage quality, addressing the limitations of current preservation methods.

JP2024544978AActive Publication Date: 2024-12-05SHANGHAI SYNVIDA BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024528505
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-15
Filing Date
2022-11-15
Publication Date
2024-12-05
Estimated Expiration
2042-11-15

AI Technical Summary

Technical Problem

Current methods for preserving platelets are limited by their sensitivity to environmental conditions, leading to irreversible changes, short shelf life, and low viability due to factors like cryopreservation-induced apoptosis and metabolic disorders, which affect their quality and longevity, necessitating improved methods to maintain or enhance platelet quality and lifespan.

Method used

The use of carnitine palmitoyltransferase II (CPT2) or its upregulators to modulate platelet viability, quality, and longevity by reducing apoptosis, improving storage quality, and extending lifespan through interventions such as reducing acetylation, enhancing activity, or increasing expression and stability of CPT2.

Benefits of technology

CPT2 upregulators effectively reduce platelet apoptosis, enhance storage quality, and extend platelet lifespan, improving their viability and quantity, addressing the limitations of current preservation methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544978000007
    Figure 2024544978000007
  • Figure 2024544978000008
    Figure 2024544978000008
  • Figure 2024544978000009
    Figure 2024544978000009
Patent Text Reader

Abstract

The present invention is a method for improving platelet quality. The present invention clarifies that the carnitine palmitoyltransferase II (CPT2) molecule located in the inner membrane of platelet mitochondria is important for the survival, preparation and storage quality of platelets, that the decrease in the expression level and / or activity of CPT2 protein has a serious effect on the quality of platelets, and that the normal or high expression of the protein improves the quality of platelets, and examines the effect of CPT2 on platelets from multiple angles by directly and indirectly affecting or modifying CPT2 protein, and discovers pathways and endogenous or exogenous molecules that play an important role in maintaining platelet viability. CPT2 itself or its upregulators can be used to maintain or improve platelet viability and maintain or improve platelet storage quality; it is also possible to screen for substances that target CPT2 or the signaling pathways in which it is involved and regulate platelet viability or improve platelet storage quality.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application claims priority to China Application No. 202111346275.7, filed on November 15, 2021. Technical Field The present invention belongs to the biomedical field, more specifically, the present invention relates to a new method for improving platelet quality. [Background technology]

[0002] Platelets are unique blood cells in mammalian blood that lack nuclei and contain intracellular structures such as mitochondria, granules, and lysosomes, and evolve by directional proliferation of hematopoietic stem cells. The lifespan of each platelet is very short, with the lifespan of platelets in the body's blood circulation being approximately 7-14 days. Once platelets have completed their life cycle and become senescent, the spleen and liver remove old platelets.

[0003] The platelet count in human peripheral blood is usually about 1-3 x 10 11 Therefore, it is very important to maintain a constant platelet count in the peripheral blood. When a patient suffers from thrombocytopenia due to systemic anticoagulation therapy, traumatic surgery, critical bleeding, chemotherapy, radiotherapy, or the development of infection, immune thrombocytopenia, or other bleeding disorders, the number of platelets in the blood circulation decreases and the peripheral blood platelet count can drop to 2 × 10 10 If the platelet count drops below 100, severe bleeding may occur. At this time, patients need to be transfused with platelets to prevent potential uncontrollable bleeding or to correct bleeding time. However, due to clinical individual differences, the life span and quality of platelets in vivo or in vitro vary greatly. Furthermore, transfusion of apheresis platelets is currently an important clinical treatment, and the supply of apheresis platelets exceeds the demand.

[0004] Currently, platelets for clinical use are primarily obtained through monocomponent donation, where platelets are selectively collected by apheresis machines that draw the donor's blood, separate the platelets from other blood cells within the machine, and collect the concentrated platelet-rich plasma in a storage bag, while the other components of the blood are reinfused into the donor's body.

[0005] However, platelets are very sensitive to the environment, and one of the preservation methods is to prepare frozen platelets by adding glycerol and DMSO to platelets, store them at -80℃, and thaw them when used. However, irreversible fibrin precipitation may occur in the platelet product after thawing, which indicates that the platelets are already in an activated state. Frozen platelets are mainly used for emergency platelet transfusions and are used when immediate hemostasis is required. Research has shown that cryopreservation causes irreversible changes in the platelet membrane, and as a result, platelets are quickly phagocytosed and removed by macrophages in the liver and spleen after transfusion. Therefore, the storage temperature of platelets is very important for the survival of platelets in the circulatory system after transfusion. The above disadvantages limit the widespread clinical application of frozen platelets. In addition, the shelf life of apheresis platelets is only 5 days, and the aging and metabolism of platelets themselves affect their aging, apoptosis and pathological death. In addition, blood type testing and pathogenic microorganism testing are required in the early stage of platelet transfusion, resulting in a very short clinical usable period and very low viability of transfused platelets. Therefore, the field urgently needs a method to improve the lifespan and quality of platelets. Summary of the Invention [Problem to be solved by the invention]

[0006] The object of the present invention is to provide a new target, i.e., the carnitine palmitoyltransferase II (CPT2) molecule, for regulating platelet viability or quality; the object of the present invention is to provide regulatory molecules acting directly or indirectly on said target, and their applications. [Means for solving the problem]

[0007] In a first aspect of the present invention, carnitine palmitoyltransferase II (CPT2) or its upregulator provides an application in the preparation of a composition, which has the following functions: (1) maintaining or improving platelet viability, (2) maintaining or improving platelet storage quality, (3) reducing platelet apoptosis, (4) extending platelet lifespan, and / or (5) improving platelet quantity.

[0008] In one or more embodiments, the dysfunction of CPT2 leads to impaired fatty acid metabolism, affecting platelet activity, quality, quantity and / or lifespan, and the upregulator alleviates or improves this condition.

[0009] In one or more embodiments, the fatty acid metabolism disorder involves the accumulation of long chain fatty acylcarnitines (C16:0, C18:0) over time.

[0010] In one or more embodiments, the fatty acid metabolism disorder comprises an elevated concentration of fatty acylcarnitines present in platelet-rich plasma.

[0011] In one or more embodiments, the platelets are isolated platelets or in vivo platelets.

[0012] In one or more embodiments, the platelets are mammalian-derived platelets, such as human platelets, mouse platelets, monkey platelets, or artificial platelets.

[0013] In one or more embodiments, the platelets are platelet rich plasma (PRP).

[0014] In one or more embodiments, the platelets are ambient and / or refrigerated stored platelets.

[0015] In one or more embodiments, reducing platelet apoptosis means that the quantity percentage A1 of apoptotic platelets in a platelet sample after administration of the composition is reduced by at least 5%, 10%, or 20% compared to the quantity percentage A0 of apoptotic platelets in a platelet sample without administration of the composition.

[0016] In one or more embodiments, extending the lifespan of platelets means that the survival time T1 of platelets after administration of the composition is compared to the survival time T0 of platelets without administration of the composition, where T1 / T0 is extended by at least 6, 12, 24, 36, 48, or 72 hours.

[0017] In one or more embodiments, improving the platelet count means that the platelet count P1 after administration of the composition is compared to the platelet count P0 without administration of the composition, where P1 / P0 is at least 1.5, more preferably at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 50, or 100.

[0018] In one or more embodiments, the carnitine palmitoyltransferase II upregulator includes, but is not limited to, one or more of the following: (a) an agent that reduces the acetylation of carnitine palmitoyltransferase II; (b) an agent that increases carnitine palmitoyltransferase II activity; (c) an agent that increases the expression, stability or effective duration of carnitine palmitoyltransferase II.

[0019] In one or more embodiments, the upregulators of carnitine palmitoyltransferase II include, but are not limited to, one or more of the following: a reagent that targets an acetylation site of carnitine palmitoyltransferase II to reduce or eliminate acetylation of said site; preferably, said substance that reduces acetylation of carnitine palmitoyltransferase II is a protein acetylation inhibitor; preferably, said protein acetylation inhibitor comprises a downregulator that reduces acetyltransferase gene, protein expression and / or activity; preferably, said protein acetylation inhibitor is a mitochondrial protein acetylation inhibitor; preferably, said protein acetylation inhibitor has CPT2 specificity; preferably, said acetylation site is lysine 79 of carnitine palmitoyltransferase II; preferably, said reagent comprises, but is not limited to, a site-directed mutagenesis reagent or a site-directed modification reagent; preferably, said downregulator that reduces acetyltransferase gene, protein expression and / or activity comprises gene editing, gene knockout, siRNA, microRNA, or a small molecule downregulator; preferably, said protein acetylation inhibitor is SIRT3 or an activator thereof; CPT1 inhibitors; preferably, said CPT1 inhibitors include CPT1 autoinhibitors, upstream AMPK inhibitors (AMPKi), ACC agonists; preferably, said CPT1 inhibitors include, but are not limited to, Malonyl-CoA, Etomoxir, Perhexiline maleate, Dorsomorphin 2HCl; Protein acetylation inhibitors; preferably including, but not limited to, lysine acetyltransferase inhibitors, mitochondrial protein acetylation inhibitors, or activators or expression upregulators thereof; preferably, said lysine acetyltransferase inhibitors include, but are not limited to, tip60 inhibitors or p300 inhibitors; preferably, said mitochondrial protein acetylation inhibitors include, but are not limited to, SIRT3; preferably, activators of SIRT3 (direct or indirect activation) include, but are not limited to, agents that increase the concentration of NAD[+] precursors or agents that increase NAMPT enzyme activity; preferably, said agents that increase the concentration of NAD[+] precursors include, but are not limited to, nicotinamide mononucleotide (NMN), nicotinamide (NAM), nicotinamide riboside (NR); preferably, said agents that increase NAMPT enzyme activity include, but are not limited to, P7C3, SBI-797812; AMPK inhibitors (AMPKi); preferably including but not limited to Dorsomorphin 2HCl; Antioxidants; preferably including but not limited to N-acetylcysteine ​​(NAC), mesna or glutathione; An expression construct (including an expression vector) for recombinantly expressing carnitine palmitoyltransferase II; An upregulator that enhances the driveability of the carnitine palmitoyltransferase II gene promoter; or Downregulator of carnitine palmitoyltransferase II gene-specific microRNA.

[0020] In one or more embodiments, the expression construct (expression vector) comprises a viral vector, a non-viral vector, preferably, the expression vector comprises an adeno-associated viral vector, a lentiviral vector, or an adenoviral vector.

[0021] In one or more embodiments, the acetyltransferase includes, but is not limited to, a tip60 inhibitor or a p300 inhibitor.

[0022] In another aspect of the present invention, a method for preserving platelets in vitro is provided, the method comprising preserving platelets by a treatment selected from the following, but not limited to: (a) reducing acetylation of carnitine palmitoyltransferase II; (b) increasing carnitine palmitoyltransferase II activity; (c) increasing the expression, stability or effective duration of carnitine palmitoyltransferase II; or (d) adding active carnitine palmitoyltransferase II (a non-acetylated enzyme).

[0023] In one or more embodiments, the dosage of the tip60 inhibitor is 0.1 to 100 umol / L (e.g., 0.5, 1, 2, 5, 10, 20, 30, 50, 60, 80 umol / L).

[0024] In one or more embodiments, the dosage of the p300 inhibitor is 0.1 to 100 umol / L (e.g., 0.5, 1, 2, 5, 10, 20, 30, 50, 60, 80 umol / L).

[0025] In one or more embodiments, the dosage (final concentration) of NMN is 0.05 to 50 mM (e.g., 0.08, 0.1, 0.2, 0.5, 0.8, 1, 1.5, 2, 3, 5, or 10 mM), preferably 0.1 to 10 mM, and more preferably 0.2 to 5 mM.

[0026] In one or more embodiments, the dosage (final concentration) of nicotinamide is 0.05 to 10 mM (e.g., 0.08, 0.1, 0.2, 0.5, 0.8, 1, 1.5, 2, 3, 5, or 10 mM), preferably 0.1 to 10 mM, and more preferably 0.2 to 5 mM.

[0027] In one or more embodiments, the dosage (final concentration) of the nicotinamide riboside is 0.05 to 50 mM (e.g., 0.08, 0.1, 0.2, 0.5, 0.8, 1, 1.5, 2, 3, 5 or 10 mM), preferably 0.1 to 10 mM, and more preferably 0.2 to 5 mM.

[0028] In one or more embodiments, the dosage (final concentration) of P7C3 is 0.025 to 50 uM (e.g., 0.04, 0.05, 0.2, 0.4, 0.5, 1, 2.5, 4, 5, 8, 10, 15, 25 or 40 uM), preferably 0.05 to 30 uM, more preferably 0.25 to 15 uM.

[0029] In one or more embodiments, the dosage (final concentration) of SBI-797812 is 0.1 to 200 uM (e.g., 0.15, 0.2, 0.8, 1.5, 2, 4, 10, 15, 20, 30, 40, 60, 100 or 150 uM), preferably 0.2 to 120 uM, more preferably 1 to 60 uM.

[0030] In one or more embodiments, the dosage of Dorsomorphin 2HCl is 0.05 to 80 uM (e.g., 0.08, 0.1, 0.15, 0.2, 0.3, 0.5, 0.5, 1, 2, 5, 10, 15, 20, 30, 40, 60, or 70 uM), preferably 0.1 to 50 uM, and more preferably 0.5 to 20 uM.

[0031] In one or more embodiments, the dosage of N-acetylcysteine ​​is 0.05 to 500 mM (e.g., 0.08, 0.1, 0.2, 0.5, 0.8, 1, 1.5, 2, 3, 5, 10, 20, 50, 80, 100, 200 mM).

[0032] In one or more embodiments, the dosage of mesna is 1-1000 uM (e.g., 1.5, 2, 4, 10, 15, 20, 30, 40, 60, 100, 150, 200, 400, 600, 800 uM).

[0033] In one or more embodiments, the dosage of glutathione is 10-2000 uM (e.g., 15, 20, 30, 40, 60, 100, 150, 200, 400, 600, 800, 1000, 1200, 1500, 1800 uM).

[0034] In one or more embodiments, the above "dosage" includes the "amount added," and preferably includes the final concentration of the corresponding additive in a composition (including the compositions below), in platelets or in a substance containing platelets.

[0035] In one or more embodiments, the "platelet-containing material" includes naturally collected (e.g., freshly collected) platelet-containing blood / plasma, platelet-rich blood products, and blood processed products.

[0036] In another aspect of the present invention, a method for maintaining or improving platelet viability is provided, comprising administering to a subject in need of improving platelet viability a treatment selected from the following, but not limited to: (a) reducing acetylation of carnitine palmitoyltransferase II; (b) improving carnitine palmitoyltransferase II activity; (c) improving the expression, stability or effective duration of carnitine palmitoyltransferase II; or (d) adding active carnitine palmitoyltransferase II (the non-acetylated enzyme).

[0037] In a first aspect of the present invention, there is provided a composition having the following functions: (1) maintaining or improving platelet viability, (2) maintaining or improving platelet storage quality, (3) reducing platelet apoptosis, (4) extending platelet lifespan, and / or (5) improving platelet quantity; said composition comprising an upregulator of carnitine palmitoyltransferase II.

[0038] In one or more embodiments, the composition comprises a protein acetylation inhibitor, an antioxidant and a CPT1 inhibitor.

[0039] In one or more embodiments, the protein acetylation inhibitor is NMN, the antioxidant is NAC, and the CPT1 inhibitor is an AMPKi.

[0040] In one or more embodiments, the molar ratio of the NMN, NAC and AMPKi is (50-500):(500-5000):1; more preferably, (80-300):(800-3000):1 (e.g., 90:900:1, 100:1000:1, 110:1110:1, 120:1200:1, 125:1250:1, 140:1400:1, 150:1500:1, 180:1800:1, 200:2000:1, 250:2500:1, etc.).

[0041] In one or more embodiments, when NMN, NAC and AMPKi are used in combination, the concentration of the NAD+ precursor NMN added to platelets or a substance containing platelets (e.g., plasma, platelet-rich plasma, etc.) is 0.1 to 5000 uM (e.g., 0.2, 0.5, 1, 2, 5, 10, 20, 50, 100, 200, 500, 800, 1000, 1500, 2000, 3000, 4000 uM).

[0042] In one or more embodiments, when NMN, NAC and AMPKi are applied in combination, the concentration of N-acetylcysteine ​​added to platelets or a substance containing platelets is 1 to 50,000 uM (e.g., 2, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 8000, 10000, 15000, 20000, 30000, 40000 uM).

[0043] In one or more embodiments, when NMN, NAC and AMPKi are used in combination, the concentration of the AMPKi added to platelets or a substance containing platelets is 0.8 to 40,000 nM (e.g., 1.6, 4, 8, 16, 40, 80, 160, 400, 800, 1600, 4000, 6400, 8000, 12000, 16000, 24000, 32000 nM).

[0044] In another aspect of the invention, a kit is provided containing the above-described composition.

[0045] Another aspect of the present invention provides the following applications of the composition or kit: (1) maintaining or improving platelet viability; (2) maintaining or improving platelet storage quality; (3) reducing platelet apoptosis; (4) extending platelet lifespan and / or (5) improving platelet quantity.

[0046] In another aspect of the present invention, there is provided an application of carnitine palmitoyltransferase II in screening of drugs (i.e., as a target for drug screening), the drugs having functions selected from the following: (1) maintaining or improving platelet viability; (2) maintaining or improving platelet storage quality; (3) reducing platelet apoptosis; (4) extending platelet lifespan and / or (5) improving platelet quantity.

[0047] In another aspect of the invention, there is provided a method for screening for a drug (or potential drug) that maintains or improves platelet viability and maintains or improves storage quality of platelets, the method comprising: (1) treating an expression system expressing carnitine palmitoyltransferase II with a candidate substance; and (2) detecting carnitine palmitoyltransferase II from the system; and determining whether the candidate substance has any of the following properties, which indicate that the candidate substance is a desired (interesting) drug: (i) weakening or loss of acetylation at an acetylation site of carnitine palmitoyltransferase II; preferably, said acetylation site is lysine 79 of carnitine palmitoyltransferase II; (ii) increasing the expression of carnitine palmitoyltransferase II; or (iii) Enhancement of carnitine palmitoyltransferase II activity.

[0048] In one or more embodiments, step (1) includes, in a test group, adding a candidate substance to the expression system; and / or step (2) includes detecting carnitine palmitoyltransferase II from the system and comparing it with a control group, where the control group is an expression system to which the candidate substance is not added; if the candidate substance statistically enhances the performance of carnitine palmitoyltransferase II described in any one of (i) to (iii) (e.g., by 20% or more, preferably by 50% or more, more preferably by 80% or more), then the candidate substance is indicated as a desired (interesting) drug.

[0049] In one or more embodiments, the system is selected from a cell system (or a cell culture system), a sub-cell system (or a sub-cell culture system), a solution system, a tissue system, an organ system, or an animal system.

[0050] In one or more embodiments, the candidate substances include, but are not limited to, overexpression molecules (e.g., constructs, activity-promoting molecules, small chemical molecules, interacting molecules, etc.) designed against carnitine palmitoyltransferase II, fragments or variants thereof, its encoding gene or upstream / downstream molecules or signal transduction pathways.

[0051] In one or more embodiments, the method further includes conducting further cell and / or animal experiments on the obtained drugs or compounds (potential drugs or compounds) to further select and determine from the candidate substances compositions useful for maintaining or improving platelet viability, maintaining or improving platelet storage quality, etc.

[0052] Another aspect of the present invention provides a genetically engineered platelet or its precursor, said platelet or its precursor being transformed with an exogenous carnitine palmitoyltransferase II or its upregulator; preferably said upregulator is a biological molecule, such as a polynucleotide or a construct or protein comprising a polynucleotide. Preferably, said upregulator is a reagent that targets the acetylation site of said carnitine palmitoyltransferase II to weaken or eliminate acetylation at said site, more preferably, mutates the lysine at position 79 of carnitine palmitoyltransferase II as the acetylation site.

[0053] In one or more embodiments, the precursors are megakaryocytes and / or fibroblasts.

[0054] In another aspect of the invention, there are provided compositions / culture systems (cultures) containing the genetically engineered platelets or precursors thereof described above.

[0055] In another aspect of the invention, there is provided a kit comprising the genetically engineered platelets or precursors thereof, or the composition / culture system (culture) described above. Effect of the Invention

[0056] Based on the disclosure herein, other aspects of the invention will be apparent to those of ordinary skill in the art. [Brief description of the drawings]

[0057] [Figure 1] Figure 1A. Analysis of platelets stored for different days showed that with increasing storage time, platelet function declined and the apoptotic rate of platelets gradually increased. Figure 1B. Real-time detection by Western blot experiment showed that the activation degree of Caspase 3 increased with increasing storage days of platelets. The molecular weight of Caspase 3 is 35 kd, and the molecular weight of shear-activated Caspase 3 is 17 kd. [Diagram 2] Figure 2A. Quantitative proteomics study of acetylation modification of stored platelets on different storage days showed that the degree of protein modification of platelets changed significantly during storage, and the protein acetylation degree of platelets changed significantly when platelets were stored for 3 to 4 days. Figure 2B. According to the statistical analysis of the intracellular structure of differentially expressed proteins, as many as one-quarter of the protein types were derived from mitochondria. Figure 2C shows the analysis on the cluster analysis heat map based on KEGG pathway enrichment based on the experimental results. Proteins with changed degrees of acetylation modification were mainly distributed in the cytoplasm and mitochondria, and most of the proteins with changed degrees of acetylation modification were found to be involved in biochemical processes such as platelet activation and metabolism. Many metabolic enzymes, such as glutamic oxaloacetic transaminase (GOT2), propionyl-CoA carboxylase (PCCA), dihydrolipoic acid dehydrogenase (DLD), acyl-CoA dehydrogenase (ACADM), carnitine palmitoyltransferase 2 (CPT2), cholesterol acyltransferase 1 (ACAT1), mitochondrial trifunctional protein (HADHA / HADHB), and very long-chain acyl-CoA dehydrogenase (ACADVL), have been found to undergo acetylation modification. [Diagram 3]Figure 3A. Quantitative proteomic analysis of acetylation modification revealed that lysine 79 of CPT2 was acetylated in platelets. Figure 3B. Dot blot experiments confirmed that the CPT2K79AC antibody bound only to acetylated peptides and did not recognize non-acetylated peptides. Figure 3C. Immunoprecipitation and Western blot experiments confirmed that the degree of acetylation at position 79 of CPT2 molecules changed with storage time, suddenly increasing when platelets were stored on the second day and gradually decreasing during the subsequent storage periods. [Figure 4]Figure 4A. Metabolic flux analysis of platelets was performed to trace the final metabolic pathways of various energy substances with stable isotope markers. During platelet storage, the efficiency of fatty acid metabolism was very low and slowed down as the storage days increased; glucose mainly produced lactate through the glycolysis pathway; glutamine was preferentially utilized and entered the tricarboxylic acid cycle in large amounts to provide energy to cells. Figure 4B. During platelet storage, the content of fatty acylcarnitines in plasma accumulated. Platelets were sampled every day during storage, and plasma was collected for mass spectrometry detection. A non-derivatization method was used for sample pretreatment, and fatty acylcarnitines with stable isotope markers were added as standards. More than 70 types of fatty acylcarnitines were detected using an ultra-high performance liquid chromatography triple quadrupole mass spectrometry system. Figure 4C. Flow cytometry was used to detect the effects of palmitic acid, palmitic acid plus carnitine, and palmitacylcarnitine on platelet preservation, and the reference indicators included platelet activity, Annexin V, and the fluorescence value of mitochondrial Mitosox. Figure 4D. Liquid chromatography-mass spectrometry tandem technology was used to detect that acetylation at position 79 of CPT2 molecule caused accumulation of fatty acylcarnitine in cells. The accumulation of fatty acylcarnitine further affected the state of cells. Flow cytometry analysis showed that with the increase in the concentration of fatty acylcarnitine, the apoptosis rate of cells and the level of reactive oxygen species in mitochondria increased. Figure 4E. Transmission electron microscopy data showed that the mitochondria of CPT2 cells and KR cells were healthy and the mitochondria were correctly aligned. However, the mitochondria in KQ cells showed inner membrane destruction and decreased electron density. When cells were exposed to low concentrations of palmitoyl fatty acylcarnitine, KR mitochondria could maintain normal structure. [Diagram 5]Figure 5A. Reducing the acetylation degree of platelet proteins can effectively improve platelet quality. The effect of reducing the acetylation degree of platelet proteins on platelet quality is observed by adding two representative acetylase inhibitors to apheresis platelets. The quality of apheresis platelets stored for 7 days was significantly improved in both the experimental group with the addition of tip60 inhibitor and the experimental group with the addition of p300 inhibitor, compared with the control group. Figure 5B. Deacetylation modification of platelet proteins plays an important role in the aging process of platelet storage. Platelets from mice with SIRT3 knockout were more prone to apoptosis during storage, had a faster decline in mitochondrial membrane potential, and accumulated more reactive oxygen species during metabolism than platelets from mice in the control group. Figure 5C. Compared with wild-type mice, the acetylation degree of position 79 of the cpt2 molecule in mice with SIRT3 knockout was higher. During storage of mouse platelets, the acetylation degree of position 79 of the cpt2 molecule increased, but the increase was more pronounced in mice with sirt3 knockout. Figure 5D. Fatty acid metabolism disorders occurred in preserved mouse platelets. As the storage time of platelets increased, the content of long-chain fatty acylcarnitines in platelets continued to accumulate, and the degree of acetylation of mitochondrial proteins had a significant effect on the content of long-chain fatty acylcarnitines in platelets. The addition of all four compounds improved the quality of platelets. Figure 5E. Through the alignment of the amino acid sequences of CPT2 molecules from different organisms, rats were found to be the natural CPT2K79R model. Comparing the storage conditions of mouse platelets and rat platelets, rat platelets were found to be more resistant to storage. Mouse platelets are more sensitive to fatty acylcarnitines, and fatty acylcarnitines effectively damage mouse platelets, while rat platelets can tolerate a certain concentration of fatty acylcarnitines. Figure 5F. Platelets from the rat CPT2K79R model resist the accumulation of fatty acylcarnitines in cells, ensuring the normal metabolism of fatty acids, and thereby protecting cells from apoptosis.Figure 5G. The content of fatty acylcarnitines in mouse platelets fluctuated rapidly with increasing storage time. The content of fatty acylcarnitines suddenly increased on the second day of storage and then rapidly decreased as most platelets underwent apoptosis. [Figure 6] Figure 6A. Western blot technique detected that AMPK-ACC signaling pathway was gradually activated during platelet storage, and abnormality in platelet energy metabolism caused phosphorylation of AMPK, and phosphorylated and activated AMPK phosphorylated its downstream substrate ACC. When the activity of phosphorylated ACC decreased, the anabolic activity of fatty acids decreased and the catabolic activity increased. Figure 6B. Shows the effects of different concentrations of AMPK inhibitors and agonists on stored platelets. The activation and inhibition of AMPK pathway are closely related to the storage quality of platelets. By adding different concentrations of AMPK inhibitors and agonists to platelets, it was found that the activation of AMPK pathway is closely related to the apoptosis, mitochondrial potential difference, accumulation of reactive oxygen species, and aggregation activity of stored platelets. And such effects are concentration-dependent. [Figure 7] Small molecule inhibitors of antioxidant activity (acetylcysteine, mesna, glutathione) can reduce the accumulation of reactive oxygen species in mitochondria, thereby protecting platelet responsiveness to stimulants and the mitochondrial potential, while also reducing the rate of apoptosis in stored platelets. [Figure 8]Figure 8A. The combination of the three compounds, NAD+ precursor NMN, ROS scavenger NAC, and AMPK inhibitor (AMPKi) (in freshly collected platelets, NMN was added at 0.5 mM, NAC was added at 5 mM, and AMPKi was added at 4 uM), improved the quality of stored platelets better than any other compound, reduced platelet apoptosis by half, and improved platelet activity by about 4 times compared to the control group. Figure 8B. Human platelet concentrates were stored in vitro for 6 days with the addition of NMN+NAC+AMPKi (NMN 0.5 mM, NAC 5 mM, AMPKi 4 μM) or PBS as a control. They were then labeled with biotin and injected into NCG mice. Compared to the control group, the platelet clearance rate of the NMN+NAC+AMPKi group was lower. Figure 8C. Mouse platelet-rich plasma (PRP) was stored in vitro for 1 day and then supplemented with NMN, NAC, AMPK inhibitor, NMN+NAC+AMPK inhibitor (NMN 0.5 mM, NAC 5 mM, AMPKi 4 uM) or PBS as a control. Platelets were then labeled with biotin and injected into WT mice. Platelets stored with NMN, NAC, or AMPK inhibitor had higher in vivo survival rates than controls, with additive effects of the combination of the three compounds. Figure 8D. The effects of NMN, NAC, or AMPK inhibitor on platelet survival in ITP patients were evaluated. An ITP mouse model was established by injecting a low dose of anti-GPIb antibody R300 into the tail vein. Platelet survival and platelet count recovery rates in the NMN, NAC, or AMPK inhibitor groups, especially the NMN+NAC+AMPKi group (dosage 1 μmol NMN, 10 μmol NAC, 8 nmol AMPKi), were higher than those in the control group. FIG. 8E. Schematic diagram of the intracellular mechanism of action involving CPT2. [Figure 9] The platelet aggregation activity of refrigerated platelets treated with NMN+NAC+AMPKi was significantly higher than that of the control group, and their apoptosis was significantly lower than that of the control group. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0058] Through research, the present inventors have found for the first time that carnitine palmitoyltransferase II (CPT2) molecule located in the inner membrane of platelet mitochondria is very important for the quality of platelet survival, preparation and storage, and that a decrease in the expression level and / or activity of CPT2 protein has a serious impact on platelet quality, while normal or high expression of the protein improves platelet quality. The present invention has verified the effect of CPT2 on platelets from multiple angles by directly and indirectly affecting or modifying CPT2 protein, and has discovered pathways and endogenous or exogenous molecules that play an important role in maintaining platelet viability. Therefore, CPT2 itself or its upregulators can be used to maintain or improve platelet viability and maintain or improve platelet storage quality; based on the function of CPT2 disclosed for the first time and the signaling pathways involved, it is also possible to screen for substances that regulate platelet viability or improve platelet storage quality; through various compounds that affect CPT2, the present invention has confirmed that NAC, NMN, and AMPK inhibitors alone and in combination can effectively extend platelet lifespan and enhance their viability, and improve platelet quality and survival cycle both in vivo and in vitro, and these drugs have already been used clinically and their safety is guaranteed.

[0059] CPT2 The amino acid sequence of human CPT2 is shown in GenBank Accession No. 1376. The present invention also includes CPT2 homologues from other species (eg, primates, rodents; specifically, monkeys, mice, etc.) and their applications.

[0060] The CPT2 of the present invention may be naturally occurring, for example, isolated or purified from human or non-human mammals. The CPT2 may also be artificially prepared, for example, recombinant CPT2 may be produced according to conventional genetic engineering recombinant techniques for experimental or clinical use. In application, recombinant CPT2 may be used. The CPT2 includes full-length CPT2 or its biologically active fragment. According to the amino acid sequence of CPT2, its corresponding nucleotide coding sequence may be easily obtained.

[0061] The present invention also includes the amino acid sequence of CPT2 with one or more amino acid residues substituted, deleted or added. CPT2 or its biologically active fragments contain some conservative amino acid substitution sequences, where the amino acid substituted sequence does not affect its activity or retains some of its activity. Appropriate substitution of amino acids is a technique well known in the art, which can be easily performed and ensures that the biological activity of the resulting molecule is not changed. These techniques have led those skilled in the art to recognize that, in general, changing a single amino acid in a non-essential region of a polypeptide does not substantially change the biological activity.

[0062] Any biologically active fragment of CPT2 can be used in the present invention. Here, a biologically active fragment of CPT2 refers to a polypeptide that can maintain all or part of the function of full-length CPT2. Usually, the biologically active fragment retains at least 50% of the activity of full-length CPT2. Under more preferred conditions, the active fragment can maintain 60%, 70%, 80%, 90%, 95%, 99%, or 100% of the activity of full-length CPT2.

[0063] Modified or improved CPT2 can also be used in the present invention, for example, to enhance its half-life, efficacy, metabolism, and / or protein effect. The modified or improved CPT2 can be a complex of CPT2 or can contain substituted or artificial amino acids. The modified or improved CPT2 may have less in common with naturally occurring CPT2, but can also maintain or improve platelet viability and maintain or improve platelet storage quality. That is, any alteration that does not affect the biological activity of CPT2 can be used in the present invention.

[0064] Applications of CPT2 and its upregulators In the present inventor's research, it is unexpectedly found that in the platelet metabolism process, the modification and differential expression of mitochondria-derived proteins, especially the acetylation of the K79 site of carnitine palmitoyltransferase II (CPT2) in the inner membrane of platelet mitochondria, have a significant impact on platelet lifespan; furthermore, the present invention confirms that the impairment of platelet fatty acid metabolism pathway caused by CPT2 dysfunction affects platelet quality through energy metabolism pathway (Figure 8E). In addition, the present invention further confirms that platelets, especially platelet quality, can be protected by directly or indirectly changing the function of CPT2, such as by directly using protein acetylation inhibitors, activating deacetylase SIRT3 gene, or indirectly intervening in the main signaling pathway of cellular energy metabolism pathway (e.g. AMPK-ACC pathway, accumulation of reactive oxygen species).

[0065] Based on the inventor's new discoveries, the present invention provides applications of CPT2 or its upregulators in the following, or as targets for drug screening: (1) maintaining or improving platelet viability; (2) maintaining or improving the storage quality of platelets.

[0066] In the present invention, the CPT2 upregulator includes, but is not limited to, substances that reduce the acetylation of CPT2; substances that enhance CPT2 activity; substances that enhance the expression, stability or effective duration of CPT2, etc.

[0067] As used herein, the CPT2 upregulator includes promoters, agonists, etc. Any substance that can improve the activity of CPT2, maintain the stability of CPT2, promote the expression of CPT2, promote the secretion of CPT2, prolong the effective effect time of CPT2, or promote the transcription and translation of CPT2 can be used in the present invention as an effective substance with upregulation function.

[0068] In a preferred embodiment of the present invention, the upregulator of CPT2 includes, but is not limited to, an expression vector or expression construct that can express (preferably overexpress) CPT2 after being introduced into a cell. Usually, the expression vector includes a gene cassette, which includes a gene encoding CPT2 and an expression control sequence operably linked thereto. "Operably linked" or "operably linked" refers to a situation in which a portion of a linear DNA sequence can regulate or control the activity of another portion of the same linear DNA sequence. For example, a promoter is operably linked to a coding sequence if the promoter controls the transcription of the sequence.

[0069] In the present invention, the CPT2 polynucleotide sequence may be inserted into a recombinant expression vector, which can then be introduced into cells and overexpressed to produce CPT2. Any plasmid and vector can be used in the present invention as long as it is replicable and stable in the host. One important feature of the expression vector is that it usually contains an origin of replication, a promoter, a marker gene, and a translation control element. The expression vector includes a viral vector and a non-viral vector, and preferably, the expression vector includes, but is not limited to, an adeno-associated virus vector, a lentivirus vector, an adenovirus vector, and the like. Methods well known to those skilled in the art can be used to construct an expression vector containing a DNA sequence containing CPT2 and appropriate transcription / translation control signals. These methods include in vitro recombinant DNA techniques, DNA synthesis techniques, in vivo recombination techniques, and the like.

[0070] According to the disclosure of the present invention, acetylation of CPT2 occurs during platelet storage. Thus, the upregulator of the present invention is preferably a reagent that targets the CPT2 acetylation site and weakens or eliminates acetylation of the site, the acetylation site being lysine 79 of CPT2. Any reagent that can target and regulate the site of CPT2 or its adjacent positions, thereby reducing its acetylation level, can be used in the present invention. Preferably, the reagent includes, but is not limited to, a site-directed mutagenesis reagent or a site-directed modification reagent that targets the lysine 79. Such site-directed mutagenesis reagent or site-directed modification reagent can be prepared using various methods in the art, such as, but not limited to, gene editing technology, homologous recombination technology, etc.

[0071] In another preferred embodiment, the acetylation of CPT2 is inhibited by a protein acetylation inhibitor, which may be a lysine acetyltransferase inhibitor, a mitochondrial protein acetylation inhibitor, or an activator or expression upregulator thereof.

[0072] Lysine acetyltransferase (HAT) catalyzes the transfer of the acetyl group of acetyl-CoA to the lysine of a substrate protein, thereby affecting the function of the substrate protein.

[0073] Both tip60 and p300 are typical members of the acetyltransferase family. tip60 belongs to the MYST acetyltransferase family and plays an important regulatory role in the activation of cell cycle checkpoints and in apoptosis and autophagy. At the same time, it also plays a role in various metabolic pathways such as glucose metabolism. p300 is an important class of histone acetylase family, named p300 because of its molecular weight of 300 kd, and p300 plays a regulatory role in processes such as cell proliferation and apoptosis. P300 and tip60 are expressed in mitochondria and function as acetyltransferases in mitochondria to acetylate non-histone proteins and change the activity of proteins. According to the results of the embodiments of the present invention, the lysine acetyltransferase inhibitors (tip60 inhibitors or p300 inhibitors) can improve the storage quality of platelets by inhibiting the acetylation of proteins in platelets. This means that the reduction in the degree of acetylation of platelet proteins contributes to effectively improving the quality of platelets.

[0074] Mitochondrial protein acetylation inhibitors can also be used in the present invention. SIRT3 is a nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase, a member of the Sirtuin family, and is an important protein deacetylase in mitochondria, which acts on mitochondrial proteins such as CPT2 to cause their deacetylation. The results of the examples of the present invention show that platelets lacking SIRT3 lack the deacetylation mechanism of mitochondrial proteins, resulting in an increased degree of acetylation of mitochondrial proteins, thus affecting the preservation state of platelets. In platelets with SIRT3 knocked out, the acetylation degree at position 79 of the CPT2 molecule is high, which affects the normal physiological function of the CPT2 molecule, causes platelet fatty acid metabolism disorder, and significantly reduces the quality of platelets. Moreover, in SIRT3 knockout platelets, the level of fatty acylcarnitine is higher than that of the control group, which shows that the content of long-chain fatty acylcarnitine in platelets continues to accumulate as the storage time of platelets increases; and the acetylation degree of mitochondrial protein has a great influence on the content of long-chain fatty acylcarnitine in platelets. This indicates that the acetylation degree of enzymes related to fatty acid metabolism in platelets may change, thereby affecting the fatty acid metabolism of platelet mitochondria.

[0075] According to the results of the examples of the present invention, activators of the mitochondrial protein acetylation inhibitor SIRT3, i.e., reagents that increase the concentration of NAD[+] precursors (nicotinamide (NAM), nicotinamide riboside (NR)) or reagents that increase NAMPT enzyme activity (P7C3, SBI-797812), can significantly improve platelet quality.

[0076] In the present invention, the correlation between the main pathways of cellular energy metabolism and the quality of CPT protein and platelets was also analyzed, and it was shown that inhibition of the activation of AMP-dependent protein kinase (AMPK) has a protective effect on platelet preservation. AMPK has the function of regulating the body's energy metabolism and maintaining the balance between energy demand and supply. When the intracellular energy level decreases, the activation of AMPK is triggered, and the oxidation and synthesis metabolic pathways are regulated. Acetyl CoA carboxylase (ACC) is one of the downstream targets of AMPK, and activated AMPK inhibits its function by phosphorylating ACC, reduces malonyl CoA synthesis, increases the activity of CPT1, and promotes fatty acid oxidation. According to the results of the embodiments of the present invention, inhibiting the activation of the AMPK pathway in platelets can effectively protect the quality of stored platelets, and inhibiting the activation of the AMPK pathway reduces the catalysis of fat oxidation by CPT1, and also reduces the amount of fatty acylcarnitines entering mitochondria, which restores the function of CPT2, so that AMPK pathway inhibitors can indirectly restore the protein function of CPT2. Therefore, in another preferred embodiment, AMPK pathway inhibitors can be used to improve platelet quality, including but not limited to Dorsomorphin 2HCl.

[0077] In addition, antioxidants can reduce the accumulation of reactive oxygen species and indirectly improve the function of CPT2. Therefore, antioxidants may be used in the present invention; preferably, including but not limited to N-acetylcysteine, mesna, or glutathione.

[0078] Although the embodiments of the present invention include several representative protein acetylation inhibitors, mitochondrial protein acetylation inhibitors, AMPK pathway inhibitors, and antioxidants, it should be understood that other compounds or proteins having the same or similar functions as these inhibitors can also be used in the present invention, and analogs, derivatives, isomers, precursors, or salts of some of the compound inhibitors can also be used in the present invention.

[0079] In the present embodiment, the molecules specifically listed that affect platelet quality are all safe and available endogenous or existing clinical drugs. Therefore, the targets and their related affecting molecules discovered in the present invention can be used to improve the life span of stored platelets and platelets in physiological microenvironments, and at the same time, CPT2 can also be used as a target for genetic manipulation of platelets.

[0080] The present invention also provides a composition comprising an effective amount (e.g., 0.000001 to 20% by weight, preferably 0.00001 to 10% by weight) of the above-mentioned CPT2, or an upregulator thereof, or an analog thereof, and a pharma- ceutically acceptable carrier.

[0081] The compositions of the present invention can be used directly to improve platelet quality, including maintaining or improving platelet viability and maintaining or improving platelet storage quality, and can also be used in combination with other active or adjuvant agents.

[0082] In general, these materials can be formulated in a non-toxic, inert, pharma- ceutically acceptable aqueous carrier medium, usually at a pH of about 5-8, preferably about 6-8.

[0083] As used herein, the term "comprising" indicates that each component may be applied together in the mixture or composition of the present invention. And, the terms "consisting essentially of" and "consisting of" are included in the term "comprising". As used herein, the term "effective amount" or "effective dosage" refers to an amount that is functional or active in humans and / or animals and tolerated by humans and / or animals.

[0084] As used herein, a "pharmaceutically acceptable" ingredient is one that may be administered to humans and / or mammals without undue adverse side effects (e.g., toxicity, irritation, and allergic reactions), i.e., with a reasonable benefit / risk ratio. The term "pharmaceutically acceptable carrier" refers to a carrier used in administering a therapeutic agent, and includes various excipients and diluents.

[0085] The composition of the present invention contains a safe and effective amount of CPT2, or its upregulator (e.g., an expression vector that overexpresses CPT2), or its analog, and a pharma- ceutically acceptable carrier. Such carriers include, but are not limited to, saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. In general, the pharmaceutical formulation is required according to the administration form, and the pharmaceutical composition of the present invention is prepared into an injection, for example, by using an aqueous solution containing saline, glucose, and other auxiliary agents in a conventional manner. The pharmaceutical composition is preferably manufactured under aseptic conditions. The dosage of the active ingredient is a therapeutically effective amount. The pharmaceutical formulation of the present invention can also be a sustained release formulation.

[0086] After understanding the application of CPT2, various methods known in the art can be used to administer said CPT2, its coding gene, or its pharmaceutical composition. The administration method of said CPT2 or its upregulator is determined according to actual needs, mainly according to the type and characteristics of said upregulator, which can be evaluated by those skilled in the art. When said CPT2 is a compound, it can be administered systemically or locally to platelets in the body; when platelets are treated ex vivo, it can be added to the platelets to be treated or to the plasma containing platelets.

[0087] When the CPT2 is a gene or protein, the CPT2 or its upregulator may be directly administered to the subject by, for example, injection; alternatively, an expression unit (e.g., expression vector, virus, etc.) carrying the CPT2 gene may be delivered to a target site via a specific route to further express active CPT2. In one embodiment, the CPT2 may be directly administered to a mammal (e.g., human), or the gene encoding CPT2 may be cloned into an appropriate vector (e.g., a conventional prokaryotic or eukaryotic expression vector, or a viral vector such as a herpes virus vector or an adenovirus vector) by a conventional method, and the vector may be introduced into a cell capable of expressing the CPT2, thereby expressing the CPT2.

[0088] Targeting CPT2 for Drug Screening Once the function and mechanism of action of CPT2 are known, a substance that promotes the expression or activity of CPT2 can be screened based on the characteristics, and the substance can be used as a candidate substance for improving platelet quality. The candidate substance includes, but is not limited to, CPT2, its fragment or variant, its coding gene or its upstream and downstream molecules or overexpression molecules designed against the signal transduction pathway (e.g., constructs, activity-promoting molecules, small chemical molecules, interacting molecules, etc.).

[0089] In a preferred embodiment of the present invention, a control group can be set up during screening to more easily observe changes in expression or activity of CPT2 and the signal transduction pathway in which it is involved, or its upstream and downstream proteins, and the control group may be a CPT2 expression system or its upstream and downstream signal transduction pathway system to which the candidate substance is not added.

[0090] The expression system may be, for example, a cell (or cell culture) system, and the cell may be a cell that endogenously expresses CPT2, or a cell that recombinantly expresses CPT2. The CPT2-expressing system may be, but is not limited to, a sub-cell system, a solution system, a tissue system, an organ system, or an animal system (such as an animal model).

[0091] As a preferred embodiment of the present invention, the above method further includes conducting further cell and / or animal experiments on the obtained potential substances to further select and confirm the substances that are truly useful for improving the viability or storage quality of platelets.

[0092] The present invention is not particularly limited to the method for detecting the expression, activity, abundance or secretion status of CPT2 or its upstream and downstream signaling pathway proteins. Conventional protein quantitative or semi-quantitative detection techniques such as SDS-PAGE, Western Blot, ELISA, etc. can be used, but are not limited to these.

[0093] Meanwhile, the present invention also provides compounds, compositions, drugs, or some potential substances obtained by the screening method. The initially screened substances can form a screening library, and people can finally screen for substances that are really useful for improving platelet viability or storage quality for clinical use.

[0094] CPT2 as a target for assessing platelet quality Based on the new findings of the present invention, CPT2 may be used as a marker for evaluating platelet viability or storage quality, and platelet viability or platelet storage quality may be evaluated / detected. In particular, for detecting the acetylation site, the site is preferably lysine 79.

[0095] To detect the presence, expression status, expression level or activity of CPT2 gene, various techniques known in the art can be used, and all of these techniques are included in the present invention.For example, existing techniques such as Southern blotting, Western blotting, DNA sequence analysis, PCR, etc. can be used, and these techniques can also be used in combination.

[0096] The present invention further provides a reagent for detecting the presence and expression status of the CPT2 gene in an analyte. Preferably, when detecting gene levels, a primer that specifically amplifies CPT2 can be used; or when determining the presence or absence of the CPT2 gene, a probe that specifically recognizes CPT2 can be used; when detecting protein levels, an antibody or ligand that specifically binds to the protein encoded by CPT2 can be used to determine the expression status of the CPT2 protein. In a preferred embodiment of the present invention, the reagent is a primer that can specifically amplify the CPT2 gene or gene fragment. The design of a specific probe for the CPT2 gene is a technique well known to those skilled in the art, for example, a probe that can specifically bind to a specific site on the CPT2 gene but does not specifically bind to other genes other than the CPT2 gene and has a detectable signal is prepared. Furthermore, a method for detecting the expression status of the CPT2 protein in an analyte with an antibody that specifically binds to the CPT2 protein is also a technique well known to those skilled in the art.

[0097] In the art, it is a well-established technique to detect the acetylation level of the acetylation site of a protein. Generally speaking, two common methods can be used to determine the acetylation site: directly purify the target protein in cells for identification by mass spectrometry; use the purified target protein to carry out an acetylation reaction with acetyltransferase in vitro, and identify the target protein after the reaction by mass spectrometry. Regardless of which method is used to determine the acetylation site, it is generally necessary to construct a mutant for final confirmation. Acetylation mainly occurs on lysine (K), and generally, mutation of lysine to arginine (R) corresponds to simulating deacetylation, and mutation of lysine to glutamine (Q) corresponds to simulating acetylation.

[0098] Once the acetylation site is determined, the constructed acetylation / deacetylation simulation mutants can usually be used to study the effect of acetylation on the function of the target protein. In general, the study of protein acetylation modification involves the following steps: confirm whether acetylation exists in the target protein; screen acetylase / deacetylase enzymes; identify the acetylation site; analyze the effect of acetylation on the target protein; explore the biological function of acetylation of the target protein.

[0099] The present invention further provides a kit for detecting the presence and expression status of the CPT2 gene in an analyte, the kit comprising a reagent for specifically detecting the acetylation level of an acetylation site of the CPT2 protein, a primer for specifically amplifying the CPT2 gene, a probe for specifically recognizing the CPT2 gene, or an antibody or ligand that specifically binds to the CPT2 protein.

[0100] The kit may include various reagents necessary for DNA extraction, PCR, hybridization, color development, etc., including, but not limited to, extraction solutions, amplification solutions, hybridization solutions, enzymes, control solutions, color development solutions, washing solutions, etc. Additionally, the kit may include instructions for use and / or nucleic acid sequence analysis software.

[0101] Genetically engineered platelets or their precursors The present invention further provides a genetically engineered platelet or its precursor, wherein the platelet or its precursor is transformed with an exogenous carnitine palmitoyltransferase II or its upregulator. In a preferred embodiment, the upregulator of carnitine palmitoyltransferase II is a reagent that targets an acetylation site of carnitine palmitoyltransferase II to attenuate or eliminate acetylation at the site, more preferably, the acetylation site is lysine 79 of carnitine palmitoyltransferase II, which is mutated to attenuate or eliminate acetylation.

[0102] Platelets from various sources can be transformed with carnitine palmitoyltransferase II or its upregulator according to the present invention. These include platelets isolated from the human body, and platelets induced by differentiation of fibroblasts and megakaryocytic stem cells. The stem cells include hematopoietic stem cells, embryonic stem cells, and induced stem cells, which can be induced to differentiate in vitro to produce mature functional platelets. Platelet production is the result of the synergistic interaction of multiple cytokines in the bone marrow stromal microenvironment, and generally, a relatively complete platelet in vitro culture system can be obtained by simulating the microenvironment that produces platelets in vivo.

[0103] The present invention will be further described below with reference to specific examples. It should be understood that these examples are merely illustrative of the present invention and do not limit the scope of the present invention. Experimental methods in the following examples that do not specify specific conditions are usually carried out according to the general conditions described in J. Sambrook et al., Guide to Molecular Cloning, Third Edition, Science Press, 2002, or according to the conditions recommended by the manufacturer.

[0104] Common methods 1. Construction of CPT2K79Q point mutant mice 1.1 CPT2K79Q / R mice The amino acid sequence of CPT2 is shown in UniProtKB-P23786. Construction of CPT2K79Q mice: In the background of C57BL / 6 strain, a CPT2 gene EXON3 (K79Q: AAG → CAG) point mutation was made, and a target site ending with NGG was designed near this site, which was then cut, and an approximately 90 bp donor was constructed in vitro, and the exogenous donor was inserted into the cut site by homologous recombination. The above experimental protocol for constructing the model mice was provided by Yaobang Biological Company.

[0105] The offspring were genotyped by forward primer sequencing and using PeakChart to identify the presence of base mutations at the target positions. GuideRNA and gene sequences were as follows: CPT2-sgRNA2: tgtgttttcttgaaaattacagG (SEQ ID NO: 1) CPT2-sgRNA3: GAAGACAGAAGTGTTGTGTAAGG (SEQ ID NO: 2) CPT2(K79Q)-Oligo2: gtggtttgacctgtgttttcttgaaaattacagACAGACAGAGGTGTTGTGTAAGGATTTTGAGAACGGCATTG*G*G (SEQ ID NO: 3) CPT2(K79R)-Oligo2: gtggtttgacctgtgttttcttgaaaattacagAAGGACAGAGGTGTTGTGTAAGGATTTTGAGAACGGCATTG*G*G (SEQ ID NO: 4) 1.2 Using the same method, CPT2K79R mice were constructed, with the difference being the K79R: AAG-AGG point mutation. The guide RNA and gene sequence for base mutation identification were as follows: CPT2-sgRNA2: tgtgttttcttgaaaattacagG (SEQ ID NO: 5) CPT2-sgRNA3: GAAGACAGAAGTGTTGTGTAAGG (SEQ ID NO: 6) CPT2(K79R)-Oligo2: gtggtttgacctgtgttttcttgaaaattacagAAGGACAGAGGTGTTGTGTAAGGATTTTGAGAACGGCATTG*G*G (SEQ ID NO: 7) 2. SIRT3 gene knockout mice The background of the SIRT3 knockout mouse strain is C57BL / 6N, and the SIRT3 knockout mice were obtained using high-throughput electrotransformation of fertilized eggs. All mice were SPF (specific pathogen free) grade, had free access to water and food, and were maintained in a 40-70% humidity and approximately 23°C temperature environment, simulating a 12-hour alternating day and night cycle. They were managed and bred by the Department of Animal Science, School of Medicine, Shanghai Jiao Tong University.

[0106] 3. Identification of mouse genotypes Mice were numbered, tails clipped, and mouse genomic DNA was extracted using the absolute ethanol method and amplified by PCR, followed by gel imaging using a Gel Image System 250 gel imaging system and UV illumination.

[0107] PCR primers

[0108] [Table 1] PCR Reaction System

[0109] [Table 2] PCR reaction conditions

[0110] [Table 3] Sequencing of PCR products and genotyping The PCR products of the CPT2 point mutant mice were sequenced with the forward primer, and the returned sequences were identified and confirmed to be correct using 4PEAKS software.

[0111] Genotyping of SIRT3-KO mice: a single 500bp band indicates that the mouse is wild type, a single 100bp band indicates that the mouse is knockout type, and simultaneous appearance of 100bp and 500bp bands indicates that the mouse is heterozygous.

[0112] 4. Ambient Temperature Storage and Sample Collection of Human Apheresis Platelets An appropriate amount of apheresis platelets was added to a 50 ml centrifuge tube (volume not to exceed 15 ml / tube), and the mouth of the 50 ml centrifuge tube was covered and secured using a clinical platelet storage bag as a breathable membrane, and placed on a horizontal shaker, and the rotation speed was determined based on the volume in the tube to ensure that the platelets were sufficiently shaken and fully exposed to oxygen to breathe without touching the breathable membrane.

[0113] This method can simulate the storage of clinical apheresis platelets in a laboratory environment; it can be used for sampling and the sampling is completed. The collected apheresis platelet samples can be used for platelet counting, flow cytometry index detection, protein sampling, platelet viability detection, ATP content detection and other purposes.

[0114] 5. Storage of Mouse Platelets Abdominal aortic blood was collected from the mice, and apyrase (final concentration: 1U / ml) and PGE1 (final concentration: 0.1μg / ml), which inhibit platelet aggregation, were added to the whole blood, quickly mixed, and centrifuged (1050 rpm, room temperature, 10 min). After two centrifugations, the upper plasma layer of the experimental group was aspirated and discarded, and the platelet sediment was left at the bottom. The plasma of the wild-type mice was evenly distributed into the experimental group mice and the platelet sediment of the wild-type mice, and the platelets were evenly dispersed and suspended, and stored according to the human platelet method.

[0115] 6. Platelet aggregation function test In the conventional method, a platelet aggregator was used, and 3 × 10 8 300 μl of platelets at 1 / ml were added to the aggregation tubes, the required inhibitors were added, gently mixed, and incubated at 37° C. for 3 minutes to establish a baseline and observe changes in the aggregation curve within 5 minutes.

[0116] 7. Platelet Apoptosis Experiments According to the conventional method, platelets were sampled and diluted with Tyrode's buffer to a platelet concentration of 10^8 / ml. 25μl of platelets from the experimental group and the control group were taken and added to a new EP tube. 5μl of 10x Binding Buffer and 2μl FITC-marked Annexin V were added to each tube, and 18μl of Tyrode's buffer was added to make up the reaction system to 50μl. After 15 minutes of incubation at room temperature in the dark, 200μl of 1x Binding Buffer was added and detected by the machine. At the same time, a tube of unmarked platelets was prepared as a negative control. Platelets marked with Annexin V were detected within 1 hour after marking, and the FITC-positive cell population was platelets in the process of apoptosis.

[0117] 8. Flow Cytometric Detection of Apoptosis in Stably Transfected Cell Lines The adherent cells were collected by digestion with trypsin, centrifuged at 2000 rpm at 4°C for 5 minutes, washed several times with PBS (add 1ml PBS to the cell pellet, leave for 3 minutes, and centrifuge at 2000 rpm at 4°C for 5 minutes), completely removed residual EDTA, centrifuged, removed the supernatant, resuspended the cells, added 5μl of fluorescently marked Annexin V, mixed well, and incubated at room temperature in the dark for 15 minutes, then added 5μl of propidium iodide, continued to incubate at room temperature in the dark for 5 minutes, added 200μl × Binding Buffer, and detected by machine, and the detection was completed within 1 hour.

[0118] 9. Flow Cytometric Detection of Mitochondrial Potential 9.1 Detecting the change of platelet mitochondrial potential difference with JC1 fluorescent dye: According to the conventional method, the JC1 working solution was prepared and the platelets of the positive control group were treated with CCCP to reduce the mitochondrial membrane potential and form a positive control. Platelets were sampled and diluted for 10 min. 8 25 μl of platelets were collected, 25 μl of JC1 working solution was added, mixed, and incubated at 37°C for 30 minutes in the dark, and 200 μl of 1× JC1 staining buffer was added. The fluorescence intensity was detected by the machine, and the ratio of mitochondrial depolarization was expressed as the relative ratio of red and green fluorescence.

[0119] 9.2 Detecting changes in platelet mitochondrial potential with TMRM fluorescent dye Platelets were sampled and diluted as described above, and 50 μl of Tyrode's buffer and 0.1 μl of TMRM stock solution were added to 50 μl of the diluted solution and incubated at 37°C for 30 minutes in the dark. Then, 500 μl of Tyrode's buffer was added and detected by the machine. The fluorescence intensity of TMRM red-shifted in response to changes in mitochondrial potential, and the fluorescence intensity represents the level of mitochondrial potential.

[0120] 9.3 Detecting changes in mitochondrial potential in adherent cells with TMRM fluorescent dye Stably transfected cells were plated one day in advance, and different concentrations of fatty acylcarnitines or other inhibitors were added to different cells according to the experimental requirements. The next day, TMRM was diluted 1:1000 with cell culture medium to prepare a working solution, and the pre-prepared cell medium was replaced and placed in an incubator for 30 minutes. The cells were washed twice with ice-cold PBS, digested with trypsin, collected, centrifuged at 600g for 5 minutes to obtain cell pellets, washed twice with PBS, resuspended in 200μl PBS, and detected fluorescence by machine.

[0121] 10. Detection of Mitosox Fluorescent Dye Using conventional methods, 25 μl of platelets were diluted in equal proportions, 0.1 μl of Mitosox reagent (5 mM) was added, incubated at 37°C for 30 min in the dark, then 200 μl of buffer was added and the fluorescence intensity was detected; staining of adherent cells: centrifuged at 600g for 5 min, the supernatant was removed, the cells were resuspended in 200 μl of Mitosox working solution, incubated at 37°C for 30 min in the dark, centrifuged at 600g for 5 min, the cells were washed twice with PBS, then 200 μl of PBS was added to resuspend the cells and detected.

[0122] 11.CPT2, CPT2K79Q, CPT2K79R Plasmids and Stably Transfected Cell Lines Three plasmids, pLVX-IRES-ZsGreen1 with CPT2K79R inserted, pLVX-IRES-ZsGreen1 with CPT2K79Q inserted, and pLVX-IRES-ZsGreen1 with CPT2 inserted, were synthesized by Shanghai Sunny Biotechnology Co., Ltd. Lentiviral transfection, 293T cell infection, and stably transfected cell lines were all performed by conventional methods.

[0123] 12. Measurement of ATP content in platelets Using a commercially available ATP detection kit, 3x10 8Platelets were collected, EDTA and apyrase were added, and the platelet sediment was obtained by centrifugation. 200 μl of ATP detection dissolving solution was added to the sediment, the platelets were blown off, and the platelets were placed on ice. The platelets were centrifuged at 4°C and 12,000g for 5 minutes, and the supernatant was collected for subsequent testing. Calibration was performed and the ATP standard solution was diluted to 10, 3, 1, 0.1, and 0.01 μM / l, respectively. The ATP detection reagent and the ATP detection reagent dilution solution were mixed in a ratio of 1:9. Measurement of ATP concentration: 100 μl of ATP detection working solution was added to the detection well and left at room temperature for 3 to 5 minutes, and 20 μl of different concentrations of standards and samples to be tested were added to the detection wells of a 96-well plate in a light-shielded state, mixed quickly, and after an interval of at least 2 seconds, the fluorescence value was measured with a chemiluminescence detector (luminometer), the calibration curve was fitted, the ATP content in the samples to be tested was calculated, and the BCA protein in the remaining samples to be tested was quantified to eliminate the measurement error caused by the difference in protein amount.

[0124] 13. Mitochondrial Mitotracker Staining Mitotracker Deep Red FM-special packaging was purchased from Thermofisher Company. The experimental cells were treated one day before, and a circular glass slide was placed on the bottom of a 24-well plate to plate the cells. The cells were cultured overnight in a cell culture incubator at 37°C, and the cell density in each well was adjusted to 50% to 70% the next day. The cell culture medium in the 24-well plate was washed out and washed twice with PBS. Next, Mitotracker working solution (1 mM Mitotracker Deep Red diluted to a working concentration of 100 nM) was added to the 24-well plate. The 24-well plate was returned to a cell culture incubator at 37°C and cultured for 30 minutes. After staining, the cells were washed with PBS, slowly shaken on a horizontal shaker for 5 minutes, and replaced with fresh PBS buffer, which was repeated twice. 200μl of 4% formaldehyde was added to each well and fixed at room temperature for 10 minutes, and the cells were washed again with PBS; 200μl of ready-to-use DAPI dye was added to each well of the 24-well plate and stained at room temperature for 10 minutes under complete darkness. One drop of Anti Fade Reagent was added to the slide, and the slide was taken out of the 24-well plate, absorbed with water, and five fields were randomly selected and photographed under a fluorescent microscope to overlay different fluorescence.

[0125] 14. Monitor mitochondrial aerobic metabolism and glycolysis in platelets and stably transfected cell lines in real time with the Seahorse Metabolometer Adherent cells were seeded at a ratio of 30,000 cells / well. To test the effect of drugs on cellular respiration, inhibitors were added when the cells were seeded. Celltak was used as a cell adhesive to coat the cell culture plates, allowing the floating cells to adhere to the bottom of the Seahorse XF96 cell plates. On the day of the experiment, an appropriate amount of platelet suspension was added to the wells, and 10 platelets were added to the experimental wells for glycolysis. 7 Inoculate 2 x 10 platelets into experimental wells for cellular oxygen consumption tests. 7 were inoculated and allowed to attach to Celltak.

[0126] Preparation of two Seahorse detection solutions:

[0127] [Table 4] The pH was adjusted to 7.4 with 1 mM sodium hydroxide in a 37° C. water bath and placed in a 37° C. water bath for later use.

[0128] Methods for preparation and administration of drugs in mitochondrial stress kit and glycolysis stress kit 1) Administration scheme for detecting platelet metabolism

[0129] [Table 5] 2) Administration scheme for detecting metabolism in stably transfected cells

[0130] [Table 6] The wet test plate was removed from the carbon dioxide-free incubator, and the drug diluted to the concentration of the administration well was added to each of the three administration wells A / B / C, of ​​which 20 μl was added to well A, 22 μl to well B, and 25 μl to well C.

[0131] 15. Preparation of Bovine Serum Albumin and Stable Isotope-marked Palmitic Acid Conjugates 2.267 g of fatty acid-free bovine serum albumin was taken and added to 100 ml of 150 mM NaCl solution while stirring, and placed in a water bath at 37 °C to maintain the temperature. Separately, a 17 mM BSA control stock solution was prepared and stored at -20 °C. 30.6 mg of stable isotope-marked palmitic acid was added to 44 ml of 150 mM NaCl solution and stirred in a water bath at 70 °C. Separately, 50 ml of BSA solution was taken and 40 ml of palmitic acid solution was added in eight portions, stirred in a water bath at 37 °C for more than 1 hour, quantified to 100 ml with 150 mM NaCl solution, pH was adjusted to 7.4, and a bovine serum albumin and stable isotope-marked palmitic acid conjugate with a concentration of 1 mM was prepared and stored at -20 °C.

[0132] Freshly collected apheresis platelets were spiked with stable isotope-marked palmitic acid (final concentration 66 μM) and, in the palmitic acid-spiked experimental group, L-carnitine (final concentration 660 μM) was added at a concentration 10 times that of palmitic acid. Samples were taken daily during storage. Platelet samples were collected from the platelets stored for 0–7 days, with 3 × 10 8 Platelets were harvested, EDTA and apyrase were added to inhibit platelet aggregation and activation, centrifuged at 800g for 5 min at room temperature, the supernatant was discarded, the platelets were washed once with buffer, and centrifuged again to rapidly stop platelet metabolism. The platelet sediment was flash frozen in liquid nitrogen. Stable isotope-marked platelet samples were analyzed by Fluxomics and observed by transmission electron microscopy for changes in cellular mitochondrial morphology and internal mitochondrial structure.

[0133] 16. Construction of Mouse ITP Model WT mice were intravenously injected with NMN, NAC, AMPK inhibitor, or NMN+NAC+AMPK inhibitor, respectively. Thirty minutes later, basal platelet counts were first measured by complete blood count using a HEMAVET automated hematology analyzer. Mouse platelets were removed by intravenous injection of 2 μg of anti-CD42b monoclonal antibody R300 (purchased from Emfret). Orbital blood was collected at various time points to monitor platelet clearance and recovery.

[0134] 17. Refrigerated Storage and Sample Collection of Human Apheresis Platelets An appropriate amount of apheresis platelets was added to a 50 ml centrifuge tube (volume not exceeding 15 ml / tube), and the mouth of the 50 ml centrifuge tube was covered and fixed using a clinical platelet storage bag as a breathable membrane, and stored in a 4°C refrigerator for 3 days, followed by flow cytometry detection of platelet aggregation activity and platelet apoptosis level. 18. Data Analysis All the above experiments were performed using Graphpad Prism6 software for statistical analysis and graphing, and the data results were expressed as MEAN ± SD, and the Student's Test method was used to calculate the P value, the smaller the P value, the more significant the result, and when the P value is less than 0.05, the data is statistically significant. EXAMPLES

[0135] The quality of platelets stored on different days deteriorates over time Freshly collected apheresis platelets were taken and stored in standard disposable platelet room temperature storage bags used in clinical practice (material: butyryltri-n-hexyl citrate plasticized soft polyvinyl chloride calendared film) (purchased from Sichuan Nangel Co., Ltd.). In order to simulate the storage conditions of clinical apheresis platelets, a horizontal shaker was placed on a clean bench in the laboratory cell room and placed under standard conditions for 0 to 7 days. Apheresis platelets stored on different days were collected every day to track the function and metabolism of platelets.

[0136] In the experiment, it was found that platelets gradually lost the ability to respond to activating agents during storage, and that the ability to respond to activating agents rapidly decreased after 3 to 4 days of storage. At the same time, the mitochondrial potential of platelets also decreased with increasing storage time. The exposure level of phosphatidylserine, an indicator of cell apoptosis, continued to increase during storage. The reactivity (aggregation) of platelets to activating agents also decreased significantly on the fourth day. The level of reactive oxygen species (ROS) in platelets increased explosively on the third day of storage (Figure 1A).

[0137] Western blot analysis of Caspase 3 revealed that platelets activated Caspase 3 during storage, triggering the Caspas-mediated apoptotic pathway and causing cell apoptosis. As storage time increased, the degree of Caspase 3 activation in platelets also showed a tendency to increase. The abundance of Caspase 3 cleavage protein indicates the degree of Caspase 3 activation (Figure 1B).

[0138] This showed that during storage, platelets lost their ability to respond to activating agents, increased apoptosis, accumulated reactive oxygen species, and depolarized mitochondria, a rapid change observed after 3-4 days of storage. Detailed studies on platelet metabolism and death processes are needed to further elucidate and intervene in the influencing factors behind these phenomena. EXAMPLES

[0139] Differential expression of mitochondria-derived proteins compromises platelet quality 1. Quantitative proteomic study of acetylation in platelet samples revealed altered protein acetylation levels Archived platelet samples stored for 0–6 days were collected and platelet acetylation quantitative proteomics studies were performed by a combination of a series of techniques including TMT-mark, high-performance liquid chromatography fractionation techniques, and quantitative proteomics techniques by mass spectrometry. First, cells were lysed to extract proteins, proteins were hydrolyzed with trypsin to peptide fragments, and marked with TMT, then fractionated by high performance liquid chromatography. Then, tandem analysis of liquid chromatography and mass spectrometry was performed, and the obtained secondary mass spectrometry data was searched by Maxquant (V1.5.2.8). Finally, bioinformatics analysis was performed on the data. In this experiment, a total of 3204 proteins with quantitative information were identified. Taking 1.3-fold as the change threshold and T-Test P value < 0.05 as the standard, among the quantified proteins, in the 1d / 0d comparison group, the expression of 14 proteins was up-regulated and the expression of 6 proteins was down-regulated. In the 2d / 0d comparison group, the expression of 7 proteins was up-regulated and the expression of 6 proteins was down-regulated. In the 3d / 0d comparison group, the expression of 28 proteins was up-regulated and the expression of 21 proteins was down-regulated. In the 4d / 0d comparison group, the expression of 41 proteins was upregulated and the expression of 225 proteins was downregulated. In the 5d / 0d comparison group, the expression of 28 proteins was upregulated and the expression of 11 proteins was downregulated. In the 6d / 0d comparison group, the expression of 38 proteins was upregulated and the expression of 16 proteins was downregulated. Furthermore, analysis of acetylation modifications in platelets with altered expression revealed that the number of proteins with altered acetylation in platelets rapidly increased when platelets were stored for 3 to 4 days under conventional storage conditions (Figure 2A).

[0140] 2. Identify the location of acetylated proteins Proteins with altered acetylation levels were further subjected to bioinformatics analysis, including detailed analysis of KEGG pathways, subcellular structure localization, etc. When using Wolfpsort software to perform classification statistics on the subcellular structure of proteins that showed differential expression of acetylation on the 4th day of storage, a quarter of the protein type variety was also found to be of mitochondrial origin (Figure 2B), suggesting that storage of platelets for 4 days alters the degree of acetylation modification of a number of mitochondrial proteins. After enriching the differential proteins in different comparison groups with KEGG pathways, the inventors further performed cluster analysis to find the functional correlation of the differential proteins in the comparison groups. According to the enrichment test P value obtained by the enrichment analysis, the related functions in different groups were clustered by hierarchical clustering, and a heat map was drawn. In the heat map, the horizontal direction represents the enrichment test results of various comparison groups, and the vertical direction represents the related functional description. The color blocks corresponding to the differentially expressed proteins and functional description of different comparison groups indicate the degree of enrichment, the redder the color, the stronger the enrichment, and the bluer the color, the weaker the enrichment. The analysis of the heat map showed that the platelet activation pathway and fatty acid metabolism-related pathway had a high enrichment level, and it was found that the related proteins of these two pathways were regulated by acetylation modification during platelet storage (Figure 2C). EXAMPLES

[0141] Decreased activity of the CPT2 molecule may be associated with impaired platelet quality In Examples 1 and 2, human platelet proteome analysis was performed, and in each analysis, it was found that the acetylation degree of many enzymes involved in fatty acid metabolism changed with storage time. After further analysis, the present inventor found that carnitine palmitoyltransferase II (CPT2) molecule was acetylated with time during storage, and the acetylation occurred at lysine at position 79 (CPT2K79), which indicates that the modification of lysine at position 79 of CPT2 protein can obviously change with storage time, and the acetylation of lysine at position 79 can change the function of CPT2 molecule (Figure 3A). The present inventors prepared an antibody against the CPT2 molecule acetylated at K79 by synthesizing a peptide fragment containing CPT2 acetylated at lysine at position 79. A dot blot experiment confirmed that the antibody bound only to the acetylated peptide and did not recognize the non-acetylated peptide (Figure 3B). Using the antibody, the degree of acetylation at position 79 of CPT2 in human platelet samples stored for 0 to 7 days was detected, and immunoprecipitation and Western blot experiments revealed that acetylation of CPT2 certainly occurred during storage. Furthermore, the degree of acetylation at position 79 of the CPT2 molecule continued to increase with storage time, reaching a peak of acetylation on the second day of platelet storage, after which the acetylation at position 79 of the CPT2 molecule slowly decreased (Figure 3C). EXAMPLES

[0142] Impaired fatty acid metabolism due to CPT2 dysfunction directly impacts platelet quality CPT2 molecule is located in the inner membrane of mitochondria and is an essential catalytic enzyme in the process of fatty acid oxidation. CPT2 molecule catalyzes the decomposition of fatty acylcarnitine into fatty acyl-CoA and carnitine, and transports fatty acids into mitochondria for subsequent fatty acid oxidation. This suggests that a decrease in CPT2 protein activity may affect platelet quality through the energy metabolism pathway.

[0143] 1. The fatty acid metabolic pathway in platelets is blocked Glutamine and fatty acids are three important energy substances for living organisms. The inventors carried out experiments on C13 tracing metabolic pathways using liquid chromatography mass spectrometry, and added C13 marked palmitic acid and carnitine, C13 marked glucose, and C13 marked glutamine to a gas exchangeable professional platelet storage bag. In the experimental group supplemented with stable isotope-marked palmitic acid and carnitine, fatty acid metabolism was significantly inhibited, and the ratio of marked intermediate metabolites in the tricarboxylic acid cycle decreased with increasing storage days, indicating that fewer fatty acids undergo oxidation and enter the tricarboxylic acid cycle with increasing storage days. The fatty acid oxidation pathway is blocked during platelet storage. On the 7th day of storage, the ratio of marked malic acid and marked fumaric acid was less than 10%, indicating that the rate of fatty acid oxidation and degradation also decreased during platelet storage (Figure 4A).

[0144] 2. In fatty acid metabolism affected by CPT2 dysfunction, long-chain fatty acylcarnitines (C16:0, C18:0) accumulate over time. Fatty acids are an important source of energy for living organisms, and fatty acids generate fatty acyl-CoA in the cytoplasm through the action of fatty acyl-CoA synthase. Long-chain fatty acyl-CoA cannot pass freely through the mitochondrial membrane, and must be combined with carnitine to form fatty acylcarnitine, catalyzed by carnitine palmitoyltransferase 1 (CPT1) located in the outer membrane of mitochondria, and then enter the mitochondrial matrix to proceed to the next step of oxidation and degradation. The fatty acylcarnitine transported to mitochondria is catalyzed by CPT2, and fatty acyl-CoA and carnitine are again generated. The fatty acyl-CoA enters the mitochondrial matrix and generates acetyl-CoA under the ordered catalytic action of the β-oxidation multienzyme complex, and the acetyl-CoA finally enters the tricarboxylic acid cycle and is completely oxidized to provide energy. After observing the disorder of fatty acid metabolism in platelets, liquid chromatography-mass spectrometry was used to track the content of fatty acylcarnitines, which are intermediate products of fatty acid metabolism, and the results showed that long-chain fatty acylcarnitines (C16:0, C18:0) accumulated in the plasma of platelets, and the content of fatty acylcarnitines in plasma increased with increasing storage time. The level of fatty acylcarnitines in plasma represents the state of fatty acid metabolism, and free fatty acids need to be metabolized into fatty acylcarnitines before being transported into mitochondria through transporters on the mitochondrial membrane, and then undergo the next fatty acid oxidation metabolism to provide energy to cells. The content of fatty acylcarnitines accumulates in the early stage of platelet storage, indicating that platelets undergo very active fatty acid metabolism in the early stage of storage, and a large amount of fatty acids are metabolized into fatty acylcarnitines in preparation for the complete oxidation of fatty acids, but the activity of CPT2 protein decreases, preventing long-chain fatty acids from entering mitochondria and being metabolized to produce energy; the abnormal phenomenon of intracellular accumulation of long-chain fatty acylcarnitines indicates that the disorder of fatty acid metabolism in platelets is associated with the dysfunction of CPT2 catalytic enzyme (Figure 4B).

[0145] 3. Increased fatty acylcarnitine concentrations have a negative effect on platelet storage The accumulation of fatty acylcarnitines in platelets coincides with the increase in ROS and apoptosis observed when platelets are stored for 3-4 days. Therefore, it can be speculated that fatty acylcarnitines, which are harmful fatty acid intermediates, may induce metabolic disorders through some mechanism, thereby inducing cell apoptosis. To verify the harm of fatty acylcarnitines to platelets, palmitic acid, carnitine, palmitic acid and carnitine, and palmitoylcarnitine were added to freshly isolated platelets, and the platelets were preserved until the next day. The platelet viability was measured, and a series of mitochondrial-related indicators such as mitochondrial potential difference and mitochondrial reactive oxygen species levels were also detected. Flow cytometry detection revealed that the abnormal increase in fatty acylcarnitine concentration did not contribute to platelet preservation, and palmitoylcarnitine-added cells had a higher apoptosis rate, lower mitochondrial potential difference, and higher levels of intramitochondrial reactive oxygen species than the control group cells. At the same time, it was found that the condition of platelets in the experimental group to which fatty acids and carnitine were added simultaneously was much worse than that of the experimental groups to which only carnitine or only palmitic acid was added. This further indicates that palmitacylcarnitine, an intermediate metabolite obtained by the reaction of palmitic acid with carnitine, has a detrimental effect on platelet storage, and that fatty acylcarnitines are highly harmful intermediate metabolites of fatty acids (Figure 4C).

[0146] 4. Effect of acetylation of K79 site of CPT2 on fatty acylcarnitines To further verify the correlation between acetylation of the K79 site of CPT2 and accumulation of fatty acylcarnitines, we constructed three plasmids, CPT2 molecule / CPT2K79R mutation / CPT2K79Q mutation, packaged lentivirus with the three plasmid systems, infected 293T cell lines, and integrated the foreign gene into the host genome. Furthermore, four stably transfected cell lines were constructed through flow fluorescence screening. CPT2K79R mutates the lysine at position 79 of the CPT2 molecule to arginine, thereby losing the ability to acetylate at position 79. CPT2K79Q mutates the lysine at position 79 of the CPT2 molecule to glutamine, simulating acetylation at position 79.

[0147] We then studied various indicators of the four stably transfected cell lines, and detected the content of fatty acylcarnitines in the four stably transfected cell lines by liquid chromatography-mass spectrometry. The results showed that compared with the empty vector control group, the CPT2K79Q mutant cell line accumulated more fatty acylcarnitines, and the fatty acylcarnitine content accumulated in the CPT2K79R cell line was significantly lower than that of the CPT2K79Q cell line. Fluorescent staining and flow cytometry detection of the four stably transfected cell lines showed that the status of the CPT2K79Q cell line was obviously inferior to that of the CPT2K79R cell line, the accumulation of reactive oxygen species and the cell apoptosis rate of CPT2K79Q were significantly higher than those of the other three stably transfected cell lines, and the accumulation of reactive oxygen species and the cell apoptosis rate of the CPT2K79R cell line were significantly lower than those of the other three stably transfected cell lines (Figure 4D). Experiments show that mutation at position 79 of the CPT2 molecule has a significant effect on the accumulation of intracellular fatty acylcarnitines, the apoptosis rate, and the accumulation of mitochondrial reactive oxygen species. Acetylation at position 79 of the CPT2 molecule inhibits its function, and CPT2 acetylated at position 79 is unable to catalyze the decomposition of fatty acylcarnitines into fatty acyl-CoA and carnitine, causing the accumulation of fatty acylcarnitines in cells. At the same time, the accumulation of fatty acylcarnitines also affects the state of cells. As a toxic metabolic intermediate, fatty acylcarnitines are often used clinically as an indicator of abnormal fatty acid metabolism, and as the concentration of fatty acylcarnitines accumulates, the apoptosis rate of cells and the level of mitochondrial reactive oxygen species increase.

[0148] The above experiments confirmed that impaired CPT2 function in the CPT2K79Q cell line led to the accumulation of fatty acylcarnitines. The opposite effect was observed in the CPT2K19R cell line; impaired CPT2 function inevitably led to fatty acylcarnitines being unable to undergo further metabolism and being accumulated in mitochondria. After treating the cell lines stably transfected with CPT2 and CPT2 mutants with fatty acylcarnitines for 4 hours, the cells were fixed and electron microscopy was used to observe the state and structure of mitochondria in various cell lines treated or untreated with palmitoylcarnitine. Compared with the mitochondrial morphology of the three cell groups without palmitoylcarnitine, it could be observed that the mitochondria in the CPT2K79Q cell line had structural abnormalities, specifically, the shape and arrangement of the cristae in the mitochondria were abnormal, the structure of the cristae was disorganized, broken, or blurred, and a bright area appeared in the center of the mitochondria, indicating that the inner membrane structure of the mitochondria was severely damaged. When observing the mitochondria in the CPT2K79R cell line and the mitochondria in the CPT2 cell line, we found a clear cristae structure that was neatly arranged and had fewer bright areas, indicating that the mitochondria in the cell lines were in a healthier state. When the three cell lines were treated with low concentrations of palmitoylcarnitine and further incubated for 4 hours, the condition of mitochondria with palmitoylcarnitine was found to be significantly worse than that of the experimental group without palmitoylcarnitine. In the cells treated with palmitoylcarnitine, the inner mitochondrial membrane was further vacuolated, and the vacuoles fused with each other, resulting in multivesicular cristae. In addition, the cells treated with fatty acylcarnitines were found to have more electron-dense phagosomes, which may be lysosomes that had phagocytosed the damaged mitochondria, further indicating that the mitochondria were severely damaged. Of note, low-dose fatty acylcarnitine treatment had little effect on the condition of mitochondria in the CPT2K79R cell line, and mitochondria in the CPT2K79R cell line did not exhibit multivesicular cristae structures, even with the addition of fatty acylcarnitines. The effect of palmitoylcarnitine on the CPT2K79Q cell line, which has impaired CPT2 function, was particularly clear, as was the condition on the CPT2 cell line ( Figure 4E ).

[0149] From the above experiments the following conclusions can be drawn : 1. Palmitoylcarnitine has a toxic effect on mitochondria, affecting the morphology of cell mitochondria and, further, affecting the metabolic capacity of cells. 2. In CPT2K79Q cells, constitutive acetylation of the CPT2 molecule reduces the catalytic ability of CPT2, and mitochondria themselves accumulate more fatty acylcarnitines, which results in altered mitochondrial morphology and reduced metabolic capacity. Addition of additional fatty acylcarnitines results in CPT2 being unable to metabolize fatty acylcarnitines, leading to severe mitochondrial damage. 3. In CPT2K79R cells, the CPT2 molecule cannot be acetylated, so the catalytic ability of CPT2 is very stable, and there is less accumulation of fatty acylcarnitines in the mitochondria of the cells themselves, and the mitochondrial state is good. When additional fatty acylcarnitines are added, CPT2 can maintain sufficient activity to ensure the metabolism of fatty acylcarnitines, and can also ensure that the structure of intracellular mitochondria is not damaged even when the concentration of fatty acylcarnitines is too high. EXAMPLES

[0150] Effect of direct modulation of CPT2 function on platelet quality From the above experiments, we demonstrated that in the process of the decline of platelet quality, the expression of CPT2 was abnormal, and its effect on the platelet metabolic pathway demonstrated that abnormal CPT2 would cause abnormal fatty acid metabolism, ultimately affecting platelet quality; in order to further find ways to improve the function of CPT2 and ensure platelet quality, the following experiments were conducted.

[0151] 1.Effect of protein acetylation inhibitors on platelet quality Lysine acetyltransferase (HAT) catalyzes the transfer of the acetyl group of acetyl-CoA to the lysine of a substrate protein, thereby affecting the function of the substrate protein. Both tip60 and p300 are typical members of the acetyltransferase family. tip60 belongs to the MYST acetyltransferase family and plays an important regulatory role in cell cycle checkpoint activation, apoptosis, and autophagy. At the same time, it also plays a role in various metabolic pathways, such as glucose metabolism. p300 is an important class of histone acetylase family, named p300 because of its molecular weight of 300 kd, and p300 plays a regulatory role in processes such as cell proliferation and apoptosis. P300 and tip60 are expressed in mitochondria and function as acetyltransferases in mitochondria, where they acetylate non-histone proteins and change their activity. Freshly collected apheresis platelets were supplemented with tip60 and p300 inhibitors and stored for 7 days under standard storage conditions. After 7 days, various indicators of the stored apheresis platelets (platelet reactivity to activating agents, degree of platelet apoptosis, mitochondrial potential difference, and mitochondrial oxygen free radical levels) were detected. Experiments have found that adding an acetyltransferase inhibitor, whether it is a p300 inhibitor or a tip60 inhibitor, can effectively improve the quality of apheresis platelets by inhibiting the acetylation of intraplatelet proteins. Compared with the control group, the experimental group with the addition of tip60 inhibitor (addition amount 10uM) and p300 inhibitor (addition amount 10uM) effectively improved the responsiveness of platelets to activators, increased the platelet mitochondrial potential difference, and reduced the degree of platelet apoptosis and the content of mitochondrial reactive oxygen species (Figure 5A). This indicates that inhibiting the acetylation of intraplatelet proteins can improve the storage quality of apheresis platelets. This indicates that the degree of acetylation of platelet proteins is closely related to the storage quality of platelets. The reduction in the degree of acetylation of platelet proteins contributes to effectively improving the quality of platelets.

[0152] 2. Effects of mitochondrial protein acetylation inhibitors on platelets Silent information regulator 2-related enzyme 3 (SIRT3) is a nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase that is a member of the sirtuin family and is a key mitochondrial protein deacetylase that acts on mitochondrial proteins such as CPT2, causing their deacetylation. In this experiment, we investigated the role of SIRT3.

[0153] (1) Platelet quality is reduced in mice lacking SIRT3 First, we performed ex vivo storage experiments using platelets from SIRT3 knockout mice. Platelet pellets from wild-type and SIRT3 knockout mice were prepared in a sterile environment, and then platelets were resuspended in wild-type mouse plasma to avoid factors in the plasma interfering with the effectiveness of platelet storage. Mouse platelet-rich plasma was stored under standard clinical apheresis platelet storage conditions, and samples were taken daily to evaluate platelet status in terms of platelet apoptosis rate, mitochondrial potential difference, and accumulation of mitochondrial reactive oxygen species. The experimental results showed that, compared with wild-type control mice, platelets from mice with SIRT3 knockout underwent apoptosis faster, accumulated more reactive oxygen species in mitochondria, and decreased mitochondrial potential faster during storage (Figure 5B). This indicates that platelets lacking SIRT3 lack the deacetylation mechanism of mitochondrial proteins, resulting in an increased degree of acetylation of mitochondrial proteins, thus affecting the storage status of platelets. This further demonstrated that acetylation and deacetylation modifications of platelet proteins play an important role in the aging process of platelet storage.

[0154] (2) In mice in which SIRT3 was knocked out, CPT2 was highly acetylated at position 79. Compared with platelets from wild-type mice, platelets from SIRT3 knockout mice had a higher degree of acetylation at position 79 of CPT2 molecules. After 24 hours of storage, the acetylation degree at position 79 of CPT2 molecules in platelets from wild-type mice and SIRT3 knockout mice both increased, and the acetylation degree at position 79 of CPT2 in SIRT3 knockout mice increased significantly. Due to the lack of SIRT3 molecules in platelets, platelets from knockout mice could not undergo effective deacetylation modification during storage, resulting in a significant increase in the acetylation degree at position 79 of CPT2 molecules (Figure 5C), which affected the normal physiological function of CPT2 molecules, caused platelet fatty acid metabolism disorders, and significantly reduced the quality of platelets.

[0155] (3) Fatty acylcarnitine content is increased in platelets from mice with SIRT3 knockout Samples were collected on days 0 and 1 of storage of mouse platelets, and the content of fatty acylcarnitines in the platelets of wild-type mice and SIRT3 knockout mice was detected on days 0 and 1, respectively, mainly detecting the content of long-chain fatty acylcarnitines (palmitoylcarnitine, stearoylcarnitine). The results showed that the fatty acylcarnitine content in the platelets of wild-type mice was significantly lower than that in the platelets of mice with SIRT3 knockout. After platelet storage, the level of long-chain fatty acylcarnitine in platelets increased compared with the level of fatty acylcarnitine in fresh platelets, and the level of fatty acylcarnitine in the platelets of mice with SIRT3 knockout was higher than that of the control group. This indicates that the content of long-chain fatty acylcarnitine in platelets continues to accumulate as the storage time of platelets increases. The degree of acetylation of mitochondrial proteins greatly affects the content of long-chain fatty acylcarnitine in platelets (top of Figure 5D). This suggests that the degree of acetylation of enzymes related to fatty acid metabolism in platelets may change, thereby affecting the fatty acid metabolism of platelet mitochondria, which is consistent with the results of the decrease in CPT2 enzyme activity, further verifying the correlation between CPT2 acetylation, fatty acid metabolism disorder, and loss of platelet quality.

[0156] (4) Effect of SIRT3 activation on platelet quality SIRT3 is an NAD(+)-dependent deacetylase, and its enzymatic activity is regulated by the intracellular NAD+ (nicotinamide adenine dinucleotide) and NADH contents; an increase in the intracellular NAD+ content activates SIRT3 enzymatic activity, and conversely, an increase in the NADH content inhibits SIRT3 enzymatic activity. Nicotinamide (NAM), a precursor of nicotinamide adenine dinucleotide (NAD+), can increase the intracellular NAD+ content and enhance the activity of SIRT3; therefore, NAM is also an agonist of SIRT3, and adding NAM can indirectly enhance the deacetylation activity of SIRT3. Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme that catalyzes the synthesis of nicotinamide adenine dinucleotide (NAD+). Nicotinamide riboside (NR), also a type of NAD[+] precursor, can increase NAD[+] levels through the catalytic action of nicotinamide riboside kinase. Increased NAD[+] levels can activate SIRT1 and SIRT3, ultimately decreasing the degree of acetylation of mitochondrial proteins and enhancing oxidative metabolism. P7C3 can bind to NAMPT, enhance the activity of NAMPT enzyme, and enhance the NAMPT-mediated NAD salvage synthesis pathway, thereby increasing the intracellular NAD level. SBI-797812 is a compound that is structurally similar to nicotinamide phosphoribosyltransferase (NAMPT) inhibitors and can block the binding of NAMPT inhibitors to NAMPT. SBI-797812 shifted the NAMPT reaction equilibrium toward NMN formation, increased NAMPT affinity for ATP, stabilized NAMPT phosphorylated at His247, promoted the consumption of pyrophosphate by-products, and inactivated feedback inhibition by NAD+. To verify the ability of these substances to activate SIRT directly or indirectly through compounds that increase intracellular NAD levels, fresh apheresis platelets were collected and grouped, and then four compounds that increase NAD levels were added to the platelets, respectively, to study the effects of these compounds on platelet quality: NMN (0.1 mM, 0.5 mM), NR (0.1 mM, 0.5 mM), P7C3 (0.5 uM, 2.5 uM), and SBI797812 (2 uM, 10 uM). On the 7th day of platelet storage, platelets were collected and analyzed by flow cytometry to determine the apoptosis rate, mitochondrial potential difference, and the level of reactive oxygen species in platelet mitochondria. Platelet aggregation tests were also performed to detect the reactivity of platelets in different experimental groups to activating agents. The experimental results showed that compared with the control group, the platelet quality was improved in the experimental groups to which the four compounds were added (both the high-concentration experimental group and the low-concentration experimental group), and this improvement effect was concentration-dependent, i.e., the higher the concentration of the small molecule compound added, the greater the improvement in platelet quality. This was reflected in the improved platelet response to activating agents, the increased mitochondrial potential difference, and the decreased apoptosis rate and reactive oxygen species levels (Figure 5D, bottom). This indicates that platelet quality can be improved to different degrees whether increasing the concentration of NAD+ by increasing the concentration of precursors or by increasing the activity of the NAMPT enzyme. This also indicates that SIRT3 activity is important for platelet storage quality. Reducing the acetylation level of proteins in platelet mitochondria significantly improves platelet quality.

[0157] 3. Acetylation of the K79 site of CPT2 The above results indicate that acetylation of the K79 site of CPT2 in humans and mice plays an important role in the abnormal expression and function of CPT2 protein, thereby affecting the quality of platelets. Therefore, we compared the amino acid sequences of CPT2 molecules from several animal and plant species and found that CPT2 is a conserved protein in mammals. The 79th position of the CPT2 protein in most mammals (humans, mice, etc.) is lysine, but the 79th position of the rat CPT2 molecule is arginine (R), indicating that rats are organisms with the natural CPT2K79R mutation (Figure 5E), and therefore verified the extent of the effect of fatty acylcarnitines on rat platelets. Whole blood from wild-type rats and wild-type mice was collected by abdominal aortic blood sampling, and rat and mouse platelet-rich plasma (PRP) was prepared, respectively, for platelet storage experiments. Two experimental groups were set up to add additional palmitoyl acylcarnitine, with concentrations set as a gradient (2 μM and 10 μM), and the changes in platelet apoptosis rate, intramitochondrial reactive oxygen species content, and mitochondrial potential difference were detected during storage for 0 to 4 days, respectively. The experimental results showed that during the storage of rat platelets, the apoptosis rate and mitochondrial reactive oxygen species content were both lower than those of mice, but the mitochondrial potential difference was higher than that of mice, indicating that the condition of rat platelets was significantly better than that of mice (Figure 5F). Comparing the experimental results for 1 and 2 days, the addition of fatty acylcarnitine during storage of platelets did not significantly change the condition of rat platelets, but the addition of fatty acylcarnitine effectively reduced the condition of mouse platelets, and this effect showed a concentration-dependent tendency.

[0158] During the platelet storage period of wild-type rats and wild-type mice, platelet samples were collected daily and the fatty acylcarnitine content was detected by liquid chromatography-mass spectrometry. Analysis of the change trends of palmitoylcarnitine and stearoylcarnitine showed that the content of fatty acylcarnitines in fresh rat platelets was significantly lower than that in fresh mouse platelets, indicating that the mutation at position 79 of the rat CPT2 molecule could enhance the catalytic activity of CPT2. During storage, the content of fatty acylcarnitines in rat platelets changed smoothly and accumulated slightly on the third day of storage. However, the content of fatty acylcarnitines in mouse platelets fluctuated rapidly with the increase in storage time, and the content of fatty acylcarnitines suddenly increased on the second day of storage and then rapidly decreased as most platelets underwent apoptosis (Figure 5G). Thereby, platelets in the rat CPT2K79R model effectively resist the accumulation of intracellular fatty acylcarnitines and ensure normal metabolism of fatty acids, thereby protecting cells from early apoptosis. The experimental results again verified that acetylation at position 79 of CPT2 protein is closely related to the accumulation of fatty acylcarnitines and platelet quality. Inhibiting acetylation at position 79 of CPT2 protein can delay platelet apoptosis. Therefore, controlling the amino acid at position 79 of CPT2 protein plays an important role in platelet quality. EXAMPLES

[0159] Correlation between major pathways of cellular energy metabolism and CPT proteins and platelet quality AMP-dependent protein kinase (AMPK) regulates the body's energy metabolism and maintains the balance between energy supply and demand. When intracellular energy levels decrease, activation of AMPK is triggered, which regulates oxidative and synthetic metabolic pathways. Acetyl-CoA carboxylase (ACC) is the rate-limiting enzyme in fatty acid synthesis. Acetyl-CoA, generated by glucose metabolism, synthesizes malonyl-CoA through the action of ACC, which is the product of the first step of fatty acid synthesis, and it inhibits the activity of palmitoyltransferase 1 (CPT1) through negative feedback, thereby inhibiting fatty acid oxidation in mitochondria. ACC is one of the downstream targets of AMPK, and activated AMPK phosphorylates ACC, inhibiting its function, decreasing malonyl-CoA synthesis, increasing CPT1 activity, and promoting fatty acid oxidation (Figure 6A). Research on the embodiment of the present invention has found that during platelet storage, ATP is rapidly consumed, and the increase in ADP / ATP ratio leads to the activation of AMPK.Verification by Western blot experiment shows that AMPK is indeed phosphorylated and activated in platelets, and the downstream substrate of AMPK, acetyl-CoA carboxylase, is also phosphorylated; the activity of ACC is reduced by phosphorylation, the concentration of its metabolite, malonyl-CoA, is reduced, the inhibitory effect of malonyl-CoA on CPT1 is weakened, and a large amount of fatty acylcarnitine enters and accumulates in mitochondria through the catalytic action of CPT1, causing the dysfunction of CPT2. To examine the effect of AMPK activation on platelets, AMPK inhibitor Dorsomorphin 2HCl (1uM, 4uM) and AMPK agonist AICAR (0.1uM, 0.5uM) were added to platelets, and on the fourth day of platelet storage, flow cytometry was used to detect differences in various indicators between the experimental and control groups. The experimental results showed that in the experimental group with the addition of AMPK inhibitor, the reactivity of platelets to activators, the degree of cell apoptosis, the degree of mitochondrial reactive oxygen species, and the mitochondrial potential difference were improved to different degrees, proving that the inhibition of AMPK activation has a protective effect on platelet preservation. In the platelets of the experimental group with the addition of AMPK agonist, compared with the control group, the activation of the AMPK pathway was not only detrimental to the reactivity of platelets to activators, but also increased the rate of platelet apoptosis and was very detrimental to the mitochondrial function of platelets, the mitochondrial potential difference was significantly decreased, but the level of intramitochondrial reactive oxygen species was also increased (Figure 6B). At the same time, the experimental results after adding AMPK activator or inhibitor were obviously concentration-dependent.The experimental results showed that by inhibiting the activation of AMPK pathway in platelets, the quality of stored platelets could be effectively protected, and the inhibition of AMPK pathway activation reduced the catalysis of fat oxidation by CPT1, and also reduced the amount of fatty acylcarnitine entering mitochondria, thus reducing the burden of CPT2, so that AMPK pathway inhibitors could indirectly affect the protein function of CPT2 and reduce the accumulation of its product fatty acylcarnitine. EXAMPLES

[0160] Antioxidants reduce the accumulation of reactive oxygen species and indirectly improve CPT2 function In previous experiments, the content of reactive oxygen species was used as one of the indicators to measure platelet quality. Considering that cell apoptosis is closely related to the accumulation of reactive oxygen species, it is speculated that inhibiting the production and accumulation of reactive oxygen species in platelets would improve the quality of stored platelets and reduce the apoptosis rate of platelets. To verify this speculation, antioxidants were added to freshly collected apheresis platelets, and the reactive oxygen species content, apoptosis rate, and mitochondrial potential difference of platelets were detected on the 7th day of storage. N-acetylcysteine ​​(NAC) is a commonly used antioxidant. As a sulfhydryl-containing compound, NAC has the function of scavenging oxygen free radicals and inhibiting their synthesis. When NAC enters cells, it can produce cysteine, which promotes the synthesis of glutathione, which is the body's main weapon against oxidative stress. In addition, NAC inhibits the release of cytochrome C, thereby inhibiting the activation of caspase 3 and directly inhibiting cell apoptosis. Mesna (α-mercaptoethylsulfonic acid sodium salt) is a chemotherapy-protective agent that is widely used in clinical practice; it has significant peroxidase activity, and at the same time, it also protects the antioxidant activity of superoxide dismutase (SOD) and glutathione (GSH). Glutathione (GSH) has antioxidant and detoxifying properties. The glutathione structure contains an active sulfhydryl group (-SH) that is easily oxidized and dehydrogenated. This group makes GSH an important free radical scavenger in the body and protects sulfhydryl groups in protein and enzyme molecules. The experimental results showed that, compared with the control group, three small molecule antioxidant inhibitors, N-acetylcysteine ​​(added at 5 mM), mesna (added at 50 uM), and glutathione (added at 200 uM), could reduce the accumulation of reactive oxygen species in mitochondria to various degrees. In addition, the experiment with the addition of antioxidant small molecule inhibitors protected the reactivity of platelets to activators and the mitochondrial potential difference. At the same time, the apoptosis rate of platelets in the experimental group was also lower than that in the control group (Figure 7). This experiment further shows that reducing the content of oxygen free radicals can significantly improve the quality of platelets. EXAMPLES

[0161] The combination of a CPT2 function upmodulator, a CPT1 inhibitor and an antioxidant significantly improves platelet survival in vitro and in vivo The above experiments confirmed that NAD+ depletion, CPT2 K79 acetylation, AMPK activation, and accumulation of acylcarnitines and mtROS were the main characteristics of platelet storage injury. NMN, an NAD+ precursor, NAC, an ROS scavenger, and an AMPK inhibitor (AMPKi) significantly improved the quality of stored platelets, respectively. Therefore, the effects of the combined use of NMN, NAC, and an AMPK inhibitor on platelet storage injury merit further study. First, we investigated their effects on the platelet preservation process. The results shown in Figure 8A indicate that the triple compound combination of NMN, NAC, and an AMPK inhibitor was far superior to either of them in improving the quality of stored platelets, reducing platelet apoptosis by half and improving platelet activity by about four times that of the control group. In platelet transfusion, it is undesirable for stored platelets to be rapidly removed from the circulation. To evaluate the effect of the above compounds on the quality of stored platelets in vivo, two mouse transfusion models were used. In one model, stored human platelets were infused into immunodeficient NCG (NOD-Prkdcem26Cd52Il2rgem26Cd22 / NjuCrl) mice. Human platelet concentrates were stored ex vivo for 6 days with the addition of NMN+NAC+AMPKi (NMN 0.5 mM, NAC 5 mM, AMPKi 4 μM) or PBS as a control. They were then labeled with biotin and infused into NCG mice. Platelet counts were significantly reduced within the first 0.5 h. However, the platelet clearance rate was lower in the NMN+NAC+AMPKi group compared to the control group (Figure 8B). In another model, mouse PRP was stored ex vivo for 1 day and supplemented with NMN, NAC, AMPK inhibitor, NMN+NAC+AMPK inhibitor (NMN 0.5mM, NAC 5mM, AMPKi 4uM) or PBS as a control. Platelets were then labeled with biotin and injected into WT mice. Platelets stored with NMN, NAC, or AMPK inhibitor had higher in vivo survival rates than controls, and the combination of the three compounds was significantly superior to any of them alone (Figure 8C). EXAMPLES

[0162] Combination of CPT2 upregulator, CPT1 inhibitor and antioxidant significantly improves platelet survival in immune thrombocytopenia (ITP) ITP is an autoimmune disease characterized by low platelet counts and can lead to fatal bleeding. Previous studies have shown that in the presence of autoantibodies, platelets from ITP patients undergo damage, apoptosis, and a shortened lifespan. To evaluate the effects of NMN, NAC, or an AMPK inhibitor on platelet survival in ITP patients, an ITP mouse model was established by tail vein injection of a low dose of the anti-CD42b antibody R300. As a result, the platelet survival rate and platelet count recovery rate in the NMN, NAC, or AMPK inhibitor groups, especially the NMN + NAC + AMPKi group (dosage of 1 μmol NMN, 10 μmol NAC, 8 nmol AMPKi), were higher than those in the control group (Figure 8D). A schematic diagram of the intracellular mechanism of action involving CPT2 is shown in FIG. 8E. EXAMPLES

[0163] Combination of CPT2 up-modulator, CPT1 inhibitor and antioxidant significantly improves the quality of refrigerated platelets Low temperatures cause platelet deformation and platelet activation, which leads to rapid clearance of infused platelets. Therefore, the widespread application of refrigerated platelets is limited. However, the advantage of refrigerated platelets is that they inhibit the growth of bacteria that can cause infections. We also investigated the effects of NMN, NAC, and AMPKi on refrigerated platelets. The results show that the platelet aggregation activity of refrigerated platelets with NMN+NAC+AMPKi was significantly higher than that of the control group, and its apoptosis was significantly lower than that of the control group (Figure 9). This indicates that the combined use of NMN, NAC, and MPKi can extend the lifespan of refrigerated platelets and improve the quality of refrigerated platelets.

[0164] All references mentioned in this application are incorporated herein by reference as if each reference were incorporated solely by reference. It should be understood that based on the above disclosure of the present invention, one skilled in the art may make various changes or modifications to the present invention, and equivalents thereof are also included within the scope defined in the claims appended hereto.

Claims

1. The application of carnitine palmitoyltransferase II or its upregulator in the preparation of a composition, said composition having the following functions: (1) maintaining or improving platelet viability, (2) maintaining or improving platelet storage quality, (3) reducing platelet apoptosis, (4) extending platelet lifespan, and / or (5) improving platelet quantity.

2. The upregulator of carnitine palmitoyltransferase II is (a) a substance that reduces the acetylation of carnitine palmitoyltransferase II; (b) a substance that enhances the activity of carnitine palmitoyltransferase II; (c) a substance that enhances the expression, stability or effective duration of carnitine palmitoyltransferase II.

2. The application of claim 1, further comprising one or more of the following:

3. The upregulator of carnitine palmitoyltransferase II is a reagent that targets an acetylation site of carnitine palmitoyltransferase II to reduce or eliminate acetylation of said site; preferably, said substance that reduces acetylation of carnitine palmitoyltransferase II is a protein acetylation inhibitor; preferably, said protein acetylation inhibitor comprises a downregulator that reduces acetyltransferase gene, protein expression and / or activity; preferably, said protein acetylation inhibitor is a mitochondrial protein acetylation inhibitor; preferably, said protein acetylation inhibitor has CPT2 specificity; preferably, said acetylation site is lysine 79 of carnitine palmitoyltransferase II; preferably, said reagent comprises a site-directed mutagenesis reagent or a site-directed modification reagent; preferably, said downregulator that reduces acetyltransferase gene, protein expression and / or activity comprises gene editing, gene knockout, siRNA, microRNA, or a small molecule downregulator; preferably, said protein acetylation inhibitor is SIRT3 or an activator thereof; CPT1 inhibitors; preferably, the CPT1 inhibitors include CPT1 autoinhibitors, upstream AMPK inhibitors, and ACC agonists; preferably, the CPT1 inhibitors are Malonyl-CoA, Etomoxir, Perhexiline maleate, and Dorsomorphin 2HCl; Protein acetylation inhibitors; preferably comprising a lysine acetyltransferase inhibitor, a mitochondrial protein acetylation inhibitor, or an activator or expression upregulator thereof; preferably, said lysine acetyltransferase inhibitor comprises a tip60 inhibitor or a p300 inhibitor; preferably, said mitochondrial protein acetylation inhibitor comprises SIRT3; preferably, an activator of SIRT3 comprises an agent that increases the concentration of NAD[+] precursors or an agent that increases NAMPT enzyme activity; preferably, said agent that increases the concentration of NAD[+] precursors comprises nicotinamide mononucleotide, nicotinamide, nicotinamide riboside; preferably, said agent that increases NAMPT enzyme activity comprises P7C3, SBI-797812; AMPK inhibitors; preferably including Dorsomorphin 2HCl; Antioxidants; preferably including N-acetylcysteine, mesna or glutathione; An expression construct for recombinantly expressing carnitine palmitoyltransferase II; An upregulator that enhances the driving ability of the carnitine palmitoyltransferase II gene promoter; or Downregulator of carnitine palmitoyltransferase II gene-specific microRNA; 3. The application of claim 2, further comprising one or more of the following:

4. A method for storing platelets in vitro and / or improving the quality of in vitro stored platelets, comprising carrying out a treatment selected from the following when storing platelets: (a) reducing acetylation of carnitine palmitoyltransferase II; (b) increasing carnitine palmitoyltransferase II activity; (c) increasing the expression, stability or effective duration of carnitine palmitoyltransferase II; or (d) adding active carnitine palmitoyltransferase II.

5. The method according to claim 4, characterized in that the treatment is carried out using an upregulator of carnitine palmitoyltransferase II selected from the following: an agent that targets an acetylation site of carnitine palmitoyltransferase II to reduce or eliminate acetylation of said site; preferably said agent that reduces acetylation of carnitine palmitoyltransferase II is a protein acetylation inhibitor; preferably said protein acetylation inhibitor comprises a downregulator that reduces acetyltransferase gene, protein expression and / or activity; preferably said protein acetylation inhibitor is a mitochondrial protein acetylation inhibitor; preferably said protein acetylation inhibitor has CPT2 specificity; preferably said acetylation site is lysine 79 of carnitine palmitoyltransferase II; preferably said agent comprises a site-directed mutagenesis agent or a site-directed modification agent; preferably said downregulator that reduces acetyltransferase gene, protein expression and / or activity comprises a gene knockout, siRNA, microRNA or a small molecule downregulator; preferably said protein acetylation inhibitor is SIRT3 or an activator thereof; CPT1 inhibitors; preferably, the CPT1 inhibitors include CPT1 autoinhibitors, upstream AMPK inhibitors, and ACC agonists; preferably, the CPT1 inhibitors are Malonyl-CoA, Etomoxir, Perhexiline maleate, and Dorsomorphin 2HCl; Protein acetylation inhibitors; preferably comprising a lysine acetyltransferase inhibitor, a mitochondrial protein acetylation inhibitor, or an activator or expression upregulator thereof; preferably, said lysine acetyltransferase inhibitor comprises a tip60 inhibitor or a p300 inhibitor; preferably, said mitochondrial protein acetylation inhibitor comprises SIRT3; preferably, an activator of SIRT3 comprises an agent that increases the concentration of NAD[+] precursors or an agent that increases NAMPT enzyme activity; preferably, said agent that increases the concentration of NAD[+] precursors comprises nicotinamide mononucleotide, nicotinamide, nicotinamide riboside; preferably, said agent that increases NAMPT enzyme activity comprises P7C3, SBI-797812; AMPK inhibitors; preferably including Dorsomorphin 2HCl; Antioxidants; preferably including N-acetylcysteine, mesna or glutathione; An expression construct for recombinantly expressing carnitine palmitoyltransferase II; An upregulator that enhances the driving ability of the carnitine palmitoyltransferase II gene promoter; or Downregulator of carnitine palmitoyltransferase II gene-specific microRNA.

6. A composition having one or more of the following functions: (1) maintaining or improving platelet viability, (2) maintaining or improving platelet storage quality, (3) reducing platelet apoptosis, (4) extending platelet lifespan, and / or (5) improving platelet quantity; said composition comprises an upregulator of carnitine palmitoyltransferase II, comprising one or more selected from the following: (a) an agent that reduces the acetylation of carnitine palmitoyltransferase II; (b) an agent that enhances carnitine palmitoyltransferase II activity; (c) an agent that enhances the expression, stability or effective duration of carnitine palmitoyltransferase II; preferably, said upregulator of carnitine palmitoyltransferase II comprises one or more selected from the following: a reagent that targets an acetylation site of carnitine palmitoyltransferase II to reduce or eliminate acetylation of said site; preferably, said substance that reduces acetylation of carnitine palmitoyltransferase II is a protein acetylation inhibitor; preferably, said protein acetylation inhibitor comprises a downregulator that reduces acetyltransferase gene, protein expression and / or activity; preferably, said protein acetylation inhibitor is a mitochondrial protein acetylation inhibitor; preferably, said protein acetylation inhibitor has CPT2 specificity; preferably, said acetylation site is lysine 79 of carnitine palmitoyltransferase II; preferably, said reagent comprises a site-directed mutagenesis reagent or a site-directed modification reagent; preferably, said downregulator that reduces acetyltransferase gene, protein expression and / or activity comprises gene editing, gene knockout, siRNA, microRNA, or a small molecule downregulator; preferably, said protein acetylation inhibitor is SIRT3 or an activator thereof; CPT1 inhibitors; preferably, the CPT1 inhibitors include CPT1 autoinhibitors, upstream AMPK inhibitors, and ACC agonists; preferably, the CPT1 inhibitors are Malonyl-CoA, Etomoxir, Perhexiline maleate, and Dorsomorphin 2HCl; Protein acetylation inhibitors; preferably comprising a lysine acetyltransferase inhibitor, a mitochondrial protein acetylation inhibitor, or an activator or expression upregulator thereof; preferably, said lysine acetyltransferase inhibitor comprises a tip60 inhibitor or a p300 inhibitor; preferably, said mitochondrial protein acetylation inhibitor comprises SIRT3; preferably, an activator of SIRT3 comprises an agent that increases the concentration of NAD[+] precursors or an agent that increases NAMPT enzyme activity; preferably, said agent that increases the concentration of NAD[+] precursors comprises nicotinamide mononucleotide, nicotinamide, nicotinamide riboside; preferably, said agent that increases NAMPT enzyme activity comprises P7C3, SBI-797812; AMPK inhibitors; preferably including Dorsomorphin 2HCl; Antioxidants; preferably including N-acetylcysteine, mesna or glutathione; An expression construct for recombinantly expressing carnitine palmitoyltransferase II; An upregulator that enhances the driving ability of the carnitine palmitoyltransferase II gene promoter; or Downregulator of carnitine palmitoyltransferase II gene-specific microRNA.

7. 7. The composition according to claim 6, comprising a protein acetylation inhibitor, an antioxidant and a CPT1 inhibitor; Preferably, said protein acetylation inhibitor is nicotinamide mononucleotide, said antioxidant is N-acetylcysteine, and said CPT1 inhibitor is an AMPK inhibitor; More preferably, the molar ratio of the nicotinamide mononucleotide, N-acetylcysteine ​​and the AMPK inhibitor is (50-500):(500-5000):1; more preferably, the molar ratio is (80-300):(800-3000):1; More preferably, the concentration of said nicotinamide mononucleotide added in the platelets or a substance containing platelets is 0.1 to 5000 uM; or the concentration of said N-acetylcysteine ​​added in the platelets or a substance containing platelets is 1 to 50000 uM; or the concentration of said AMPK inhibitor added in the platelets or a substance containing platelets is 0.8 to 40000 nM.

8. A kit comprising the composition according to claim 6 or 7.

9. Use of the composition of claim 6 or 7 or the kit of claim 8 in (1) maintaining or improving platelet viability; (2) maintaining or improving the storage quality of platelets; (3) reducing platelet apoptosis; (4) extending platelet lifespan and / or (5) improving platelet quantity.

10. Application of carnitine palmitoyltransferase II in screening for drugs having functions selected from the following: (1) maintaining or improving platelet viability; (2) maintaining or improving platelet storage quality; (3) reducing platelet apoptosis; (4) extending platelet lifespan and / or (5) improving platelet quantity.

11. (1) treating an expression system expressing carnitine palmitoyltransferase II with a candidate substance; and (2) Detecting carnitine palmitoyltransferase II from the system, and if the candidate substance has any of the following properties, the candidate substance is a desired drug: (i) weakening or loss of acetylation at an acetylation site of carnitine palmitoyltransferase II; preferably, said acetylation site is lysine 79 of carnitine palmitoyltransferase II; (ii) increasing the expression of carnitine palmitoyltransferase II; or (iii) improving the activity of carnitine palmitoyltransferase II A method for screening for a drug that maintains or improves platelet viability and maintains or improves the storage quality of platelets, comprising:

12. A genetically engineered platelet or precursor thereof, characterized in that the platelet or precursor thereof is transformed with an exogenous carnitine palmitoyltransferase II or an upregulator thereof; preferably, the upregulator of carnitine palmitoyltransferase II comprises one or more of the following: an agent that targets an acetylation site of carnitine palmitoyltransferase II to reduce or eliminate acetylation of said site; preferably, said agent that reduces acetylation of carnitine palmitoyltransferase II is a protein acetylation inhibitor; preferably, said protein acetylation inhibitor comprises a downregulator that reduces acetyltransferase gene, protein expression and / or activity; preferably, said protein acetylation inhibitor is a mitochondrial protein acetylation inhibitor; preferably, said acetylation site is lysine 79 of carnitine palmitoyltransferase II; preferably, said agent comprises a site-directed mutagenesis agent or a site-directed modification agent; preferably, said downregulator that reduces acetyltransferase gene, protein expression and / or activity comprises a gene knockout, siRNA, microRNA, or a small molecule downregulator; preferably, said protein acetylation inhibitor is SIRT3 or an activator thereof; Protein acetylation inhibitors; preferably comprising lysine acetyltransferase inhibitors, mitochondrial protein acetylation inhibitors, or activators or expression upregulators thereof; preferably, said mitochondrial protein acetylation inhibitor comprises SIRT3; An expression construct for recombinantly expressing carnitine palmitoyltransferase II; An upregulator that enhances the driving ability of the carnitine palmitoyltransferase II gene promoter; or Downregulator of carnitine palmitoyltransferase II gene-specific microRNA.